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4ABSTRACT
There were 12.7 million new cancer cases in 2008 worldwide and 7.6 million cancer related
deaths. Treatment results have improved constantly during the last decades and for many common
cancers such as breast cancer and prostate cancer, the 5-year survival rate is higher than 90 %.
Unfortunately there are still many cancers, such as pancreatic cancer and lung cancer, for which the
5-year survival is 5 ? 10 % or even less. In addition, most advanced cancers lack curative
treatments, underlining the need for new effective therapeutics.
Oncolytic adenoviruses provide a new therapeutic approach. Adenoviruses have many features
that make them attractive and applicable for cancer treatments. They can be modified to replicate
specifically in cancer cells and thereby causing the death of these cells (oncolysis) but sparing
healthy cells. Oncolytic adenovirus treatments are also well tolerated and they can be combined
with conventional treatments like radiotherapy or chemotherapy to provide better treatment results.
This thesis includes both pre-clinical and clinical sections. In the pre-clinical section we evaluated
the combination of replication-deficient adenoviruses and radiotherapy. The purpose was to analyze
the mechanism of radiation-mediated upregulation of adenoviral transgene expression. In the
clinical section, cancer patients were treated with oncolytic adenoviruses and the safety of the
treatments was evaluated as a single or series of treatments. Also, efficacy and immunological
responses were evaluated.
Three cancer cell lines were used in the pre-clinical studies: M4A4-LM3 (breast cancer), PC-
3MM2 (prostate cancer) and LNM35/eGFP (lung cancer). Cancer cells were exposed to radiation in
different temporal and dose schemes and infected 24 h later with various replication-deficient
adenoviruses transgenically expressing luciferase or green fluorescent protein reporters. DNA
protein kinase inhibitor, heat shock protein 90 inhibitor, and topoisomerase-I inhibitor were used to
modify the effect of radiation-induced DNA damage. The transgene expression with or without
radiation was evaluated.
Radiation increased adenovirus transgene expression regardless of the transgene, promoter, cancer
cell line or radiation dose. We showed that enhancement of transgene expression is mediated
through genotoxic stress regulation and repair. Radiation did not increase virus transduction or the
availability of viral receptors.
  One hundred and fifty seven cancer patients with advanced solid tumors were treated with six
different oncolytic adenoviruses according to the Advanced Therapy Access Program (ATAP). The
safety of adenovirus treatments was monitored by blood chemistry measurements including
clinically relevant laboratory values, cytokine measurements and CTCAE criteria analysis for all
5detected adverse events. Biological responses in patients were quantified by measuring neutralizing
antibodies and detecting viral genomes in the circulation by quantitative real time PCR (qPCR).
Elispot analysis for tumor- and adenovirus-specific T-cells was used to identify the immunological
activity caused by the treatment. RECIST analysis and tumor markers were applied to treatment
efficacy analysis. We also compared the safety and efficacy of a serial treatment scheme, three
rounds of virus within 10 weeks, to a single treatment.
 Adenovirus  treatments  were  generally  well  tolerated  and  the  most  commonly  detected  clinical
adverse events were of grade 2 or less: the most common being injection or tumor site pain, other
pain, nausea or vomiting, fever and fatigue. Six out of 157 treated patients (3.8 %) experienced a
grade 4 adverse event. Serious adverse events were seen in 11 patients (7.0 %), but no treatment
related deaths occurred. According to RECIST analysis disease control (= stable disease or better)
was seen in 40.0 – 74.0 % of patients and there was stabilization or a decrease in tumor markers for
23.1 – 70.6 % of patients. Serial treatment was as well tolerated as single treatment, but results
suggested a better median survival even though statistical significance was not reached.
The synergistic mechanisms of radiotherapy and adenoviruses have been poorly understood and
these results provide new molecular information explaining the synergy. Radiation can increase the
expression of adenoviral transgenes, which can be used for therapeutic benefit. The analyses of
patient treatments show that oncolytic adenovirus therapy is well tolerated and promising evidence
of efficacy was seen. Serial therapy seems to be more effective perhaps due to immunological
activation and these findings represent a good justification for forthcoming clinical trials.
6TIIVISTELMÄ
Maailmanlaajuisesti vuonna 2008 todettiin arviolta 12.7 miljoonaa uutta syöpätapausta sekä 7.6
miljoonaa syöpäkuolemaa. Syövän hoitotulokset ovat kehittyneet tasaisesti viime vuosien aikana ja
nykyisin Suomessa 5-vuoden  suhteellinen elossaololuku kaikki syöpätyypit huomioituna on yli 60
%. Monen yleisen syövän, kuten rinta- tai eturauhassyövän suhteellinen elossaololuku on jo yli 90
%. On kuitenkin edelleen monia syöpiä, kuten haima- ja keuhkosyöpä, joiden ennusteessa ei ole
tapahtunut merkittävää parantumista ja 5-vuoden elossaololuvut ovat jopa alle 5 – 10 %. Samoin
levinneisiin syöpiin ei ole edelleenkään tarjolla mitään parantavia hoitomuotoja.
Tarve uusille ja tehokkaille hoitomenetelmille on selvä. Onkolyyttiset adenovirukset ovat eräs
lupaava hoitomuoto. Näitä adenoviruksia on muokattu siten, että ne tuhovat spesifisesti syöpäsoluja
(onkolyysi) säästäen terveitä soluja. Lisäksi moniin perinteisiin syöpähoitoihin verrattuna
adenovirushoidon aiheuttamat haittavaikutukset ovat hyvin siedettyjä ja adenoviruksia on
mahdollista myös yhdistää esimerkiksi sädehoidon tai solunsalpaajien kanssa.
Tämä väitöskirjatyö koostuu sekä prekliinisistä että kliinisistä tutkimustuloksista. Prekliinisessä
osuudessa tutkittiin soluviljelymalleilla sädehoidon ja adenovirusgeeniterapian yhteisvaikutuksia.
Säteilyn tiedetään lisäävän adenovirusten siirtogeenien ilmentymistä ja tarkoitus oli selvittää tähän
vaikuttavia tekijöitä. Väitöskirjan kliinisessä osuudessa syöpäpotilaita hoidettiin erilaisilla
onkolyyttisillä adenoviruksilla ja ensisijainen tarkoitus oli tutkia hoidon turvallisuutta.
Turvallisuutta on vertailu myös sarjahoidon ja kertahoidon välillä. Toissijainen tavoite oli arvioida
hoitojen mahdollista tehoa ja hyötyä potilaille sekä tutkia hoidon synnyttämää immunologista
vastetta.
Prekliinisissä tutkimuksissa käytettiin kolmea solumallia: M4A4-LM3 (rintasyöpä), PC-3MM2
(eturauhassyöpä) ja LNM35/eGFP (keuhkosyöpä). Syöpäsolut säteilytettiin erilaisissa
koeasetelmissa ja infektoitiin useilla erilaisilla lisääntymiskyvyttömillä adenoviruksilla 24 h
säteilyn jälkeen. Tutkimuksessa mitattiin säteilyn vaikutusta adenoviruksen siirtogeenien
ilmentymiseen ja siirtogeeneinä käytettiin lusiferaasia sekä GFP:tä (green fluorescent protein).
Lisäksi säteilyn aiheuttamia DNA vaurioita muokattiin käyttämällä DNA-proteenikinaasiestäjää,
topoisomeraasi-I-estäjää sekä lämpösokkiproteiiniestäjää (HSP90). Siirtogeenien ilmentymistä
säteilytetyissä soluissa verrattiin käsittelemättömiin soluihin.
Säteily lisäsi adenovirusten siirtogeenien ilmentymistä riippumatta solulinjasta, siirtogeenistä,
siirtogeenin promoottorista tai sädeannoksesta. Tulokset osoittavat, että säteilyn aiheuttamien DNA-
vaurioiden ja siirtogeenien ilmentymisen välillä on yhteys ja vaurioiden korjausmekanismit liittyvät
7ilmiöön. Säteily ei kuitenkaan lisännyt adenovirusten tunkeutumista syöpäsoluihin eikä myöskään
vaikuttanut adenovirusreseptorien ilmentymiseen syöpäsoluissa.
Kliinisessä osuudessa 157 syöpäpotilasta hoidettiin kuudella eri onkolyyttisellä adenoviruksella
kokeellisen hoito-ohjelman mukaisesti (ATAP = Advanced Therapy Access Program). Potilaiden
laboratorioparametrejä sekä sytokiinipitoisuuksia seurattiin hoitojen aikana mahdollisten
haittavaikutusten arvioimiseksi ja lisäksi kaikki havaitut haittavaikutukset luokiteltiin CTCAE-
kriteeristön mukaan. Hoitojen biologista vastetta mitattiin neutraloivilla vasta-aineilla virusta
kohtaan sekä mittaamalla viruksen genomin määrää verenkierrossa hoidon jälkeen qPCR-
menetelmällä. Hoitojen aiheuttamaa immunologista T-soluvastetta määritettiin Elispot-
menetelmällä. Virushoidon tehoa arvioitiin RECIST-luokituksella sekä mittaamalla vastetta
syöpämerkkiaineissa. Sarjahoitoa, joka tarkoittaa kolmea virushoitoa 10 vk kuluessa, verrattiin sekä
turvallisuuden että tehon näkökulmasta kertahoitoon.
Yleisesti adenovirushoidot olivat hyvin siedettyjä ja tasoa 1-2 olevia haittoja näkyi kaikilla
potilailla. Yleisimmät haitat olivat: kipu kasvaimessa tai pistokohdassa, muu kipu, pahoinvointi tai
oksentelu, kuume ja väsymys. Kuudella potilaalla 157:stä (3.8 %) havaittiin tasoa 4 oleva
haittavaikutus ja vakavia hoitoon liittyviä haittoja raportoitiin kaikkiaan 11 potilaalla (7.0 %).
Hoitoon liittyviä kuolemia ei todettu. RECIST luokituksella mitattuna hoitovaste saavutettiin 40.0 –
74.0 %:lle potilaista ja kasvainmerkkiaineilla mitattuna 23.1 – 70.6 %:lle. Sarjahoito ei lisännyt
haittavaikutuksia verrattuna kertahoitoon, mutta sillä oli suotuisa vaikutus potilaiden
elossaoloaikaan joskaan ero ei ollut tilastollisesti merkittävä.
Adenovirusten ja sädehoidon yhteisvaikutukset in vitro tunnetaan puutteellisesti, mutta
tuloksemme antavat tärkeää uutta tietoa asiasta. Tulostemme mukaan säteily lisää siirtogeenien
ilmentymistä ja tätä voidaan hoidollisesti hyödyntää. Adenovirusgeeniterapiahoidot ovat turvallisia
ja lupaavia hoitovasteita saavutettiin useille potilaille. Lisäksi sarjahoito näyttää olevan
tehokkaampi ja parantavan potilaiden ennustetta mahdollisesti tehostuneen immunologisen vasteen
vuoksi. Kliinisiä kontrolloituja hoitotutkimuksia kuitenkin tarvitaan tulosten varmistamiseksi.
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REVIEW OF THE LITERATURE
1. Introduction
Worldwide, one in eight deaths is due to cancer; cancer causes more deaths than AIDS,
tuberculosis, and malaria combined. When countries are grouped according to national economy
parameters, cancer is the leading cause of death in developed countries and the second leading
cause of death in developing countries (Table 1) (American Cancer Society, 2011).  According to a
recent World Health Organization (WHO) estimate, cancer has replaced ischemic heart disease as
the overall leading cause of death worldwide in 2010 (World Health Organization, 2007).
According to estimates from the International Agency for Research on Cancer (IARC), there were
12.7 million new cancer cases worldwide in 2008 and the corresponding estimate for total cancer
deaths was 7.6 million (American Cancer Society, 2011). These numbers are estimated to be 21.4
million and 13.2 million in 2030, respectively (American Cancer Society, 2011). In Finland, almost
30,000 new cases were diagnosed and about 11,500 people died due to cancer in 2010
(www.cancerregistry.fi, 2012). The most common cancers worldwide are prostate cancer and breast
cancer, for males and females, respectively.
Table 1. Leading causes of death worldwide in developing and in developed countries in 2004
(number of deaths, thousands).
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Considering these numbers it is notable that approximately 60-70 % of all cancer deaths occur in
low- and middle-income countries even though cancer is more common in developed countries.
This is probably mostly explained by the larger population and more limited access to healthcare
providers in the low- and middle-income countries, but also economic issues such as the costs and
availability of effective cancer treatments play a significant role. Thirty percent of all cancers could
be prevented by controlling dietary and behavioral risks like high body mass index, low fruit and
vegetable intake, lack of physical activity and the use of alcohol and tobacco (www.who.int/cancer,
WHO, April 2012).
Furthermore, of considerable importance is the emotional and physical suffering caused by cancer.
All of the above descibed issues raise the most profound question in oncology: “When will there be
a cure for cancer?” To answer this question is very challenging because cancer is not just one
disease but hundreds or even thousands of different disorders that share the common feature of
unregulated cell growth that disturbs the balance of human physiology. This complexity makes the
development  of  treatment  options  difficult;  a  treatment  that  is  effective  for  a  one  type  of  cancer
might be totally ineffective for another type of cancer.
Despite this complexity, significant improvements have taken place during the last decades in the
treatment of many cancer types.  For example, the 5-year survival rate of prostate and breast cancer
is about 90 % or even higher in Finland (Figure 1). Unfortunately, there are also cancers like
pancreatic and lung cancer, the prognosis of which remains as poor as 60 years ago (Figure 1).
Another issue is the advanced metastatic solid tumors that mostly lack curative treatments. Taken
together, new innovations and treatment options are needed.
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Figure 1. Development of five-year overall survival rate for selected cancers in
Finland. Modified from: (Pukkala et al., 2011).
One promising new treatment modality involves the use of oncolytic viruses. Earlier, efforts in
adenoviral gene therapy have focused on correction of single gene defects. In the case of cancer
gene therapy, this approach is more complicated because cancer cells have various gene defects and
distorted cellular functions. Probably, it is because of this diversity why adenoviruses have failed so
far in clinical trials to fill the high expectations and only two oncolytic adenovirus products have
been approved in China in 2003 and 2005 (Guo and Xin, 2006). Thus, improvement is needed and
many challenges in adenoviral cancer gene therapy still exist (Yamamoto and Curiel, 2010): limited
tumor transduction reduces the efficacy of treatment, vector spreading within the tumor and human
body is limited, and in vivo imaging is challenging.  Pre-clinical cancer models have also
limitations. Firstly, human adenoviruses do not replicate in mouse tissues but they do replicate in
transplanted human tumors grown in immunodeficient mice, which distorts pre-clinical results and
hampers translational relevance. Secondly, the interactions between adenovirus vectors and human
immunology cannot be studied comprehensively in immunosuppressed pre-clinical models. New
pre-clinical models such as Syrian hamsters have been introduced to circumvent this limitation,
although hamsters are only semi-permissive to adenovirus replication. Thirdly, small experimental
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tumors in mice are easier to reach and treat successfully than advanced and disseminated tumors in
patients.
Adenoviral cancer gene therapy is still an attractive treatment option for cancer types resistant to
conventional treatment. There is the inherent anti-cancer efficacy via oncolysis as such, but in
addition oncolytic adenoviruses can be combined with conventional treatments like surgery,
chemotherapeutics and radiotherapy to increase the overall efficacy. In addition, adenoviruses can
be combined with modern therapies like monoclonal antibodies.
In the preclinical part of this thesis, we show in preclinical models that radiotherapy increases
adenoviral transgene expression by modulating genotoxic stress and DNA break repair. This
supports the synergy hypothesis of radiotherapy and adenoviruses that might eventually lead to
improved treatment efficacy and ultimately better survival of patients.
In the clinical part of this thesis, 157 cancer patients with advanced metastatic tumors were treated
according  to  the  Advanced  Therapy  Access  Program  (ATAP),  with  a  variety  of  oncolytic
adenoviruses. We show that the treatment is safe and well tolerated.  In addition, objective evidence
of treatment efficacy was observed. We also present new ideas to enhance adenoviral cancer gene
therapy efficacy in patients. These findings create a solid background for forthcoming clinical trials.
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2. Gene therapy
Gene therapy can be broadly defined as the use of nucleic acid as a pharmaceutical agent to treat
disease. Originally, gene therapy held promise of correcting inherited monogenic diseases by either
replacing the defective gene or introducing therapeutic genes to produce therapeutic gene products
and proteins in somatic cells (Friedmann and Roblin, 1972). In theory, germ line cells can also be
modified by gene therapy, but many ethical and legal aspects limit this approach in human subjects.
In this thesis the focus is on adenoviral cancer gene therapy, but also other human diseases have
been suggested and tested as candidates for viral gene therapy approaches. A comprehensive review
of this topic is not done, but a few examples are given:
1) Cardiovascular diseases:
Cardiovascular diseases are the leading cause of death worldwide (Table 1).
Atherosclerotic diseases are multifactorial disorders characterized by stenosis or total
occlusion of arteries causing insufficient perfusion of the target organs. The patients are
currently treated with systemic medication, using percutaneous revascularization or bypass
surgery. However, many patients cannot be effectively treated by these methods, and
vascular gene therapy has been studied as an alternative for these patients. Safety records for
cardiovascular gene therapy have been excellent, but low gene transfer efficiency hinders
this approach, as reported in several clinical trials (Hedman et al., 2011). Intra-arterial
recombinant fibroblast growth factor-2 infusion significantly increased peak walking time at
90 days in patients with moderate-to-severe intermittent claudication (Lederman et al.,
2002). Vascular endothelial growth factor (VEGF) gene therapy has been studied for
treatment of lower-limb ischemia. Angiography demonstrated that VEGF gene transfer
increased vascularity in both adenovirus encoding VEGF and VEGF-Plasmid/Liposome-
treated patients (Makinen et al., 2002).
2) Neurological diseases:
Cholinergic neuron loss is a characteristic feature in Alzheimer’s disease. Nerve growth
factor (NGF) stimulates cholinergic function, improves memory, and prevents cholinergic
degeneration. Ex vivo NGF gene delivery to patients with mild Alzheimer’s disease, by
implanting autologous fibroblasts genetically modified to express human NGF into the
forebrain suggested improvement in the rate of cognitive decline, and no long-term adverse
events occurred (Tuszynski et al., 2005).
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Neurotrophic factors can improve the function of degenerating neurons and protect against
further neurodegeneration in Parkinson’s disease. Intraputaminal injections of adeno-
associated virus serotype 2-neurturin (CERE-120) were successfully tested in a phase I trial
for  patients  with  Parkinson’s  disease.  The  safety  profile  was  extremely  good  and  no
clinically significant adverse events were detected during a one year follow-up. Several
secondary measures of motor function showed improvement after one year (Marks et al.,
2008).
3) Immunology-related genetic diseases:
Adenosine deaminase (ADA) deficiency is a fatal autosomal recessive form of severe
combined immunodeficiency (SCID) characterised by impaired immune responses and
recurrent infections (Hershfield, 1998). Toxic levels of purine metabolites can cause hepatic,
skeletal, neurological and behavioral alterations (Honig et al., 2007; Rogers et al., 2001), as
well as sensorineural deafness (Albuquerque and Gaspar, 2004). A hematopoietic stem-cell
transplant from a HLA-identical sibling is the treatment of choice, but this is available for
only  a  minority  of  patients  (Buckley  et  al.,  1999;  Grunebaum et  al.,  2006).  ADA was  the
first genetic disorder treated by gene therapy since the beginning of the 1990s when ADA-
gene-corrected T-cells were used (Bordignon et al., 1995). However, the long-lasting
treatment efficacy was limited and all patients required maintenance of polyethylene glycol–
modified bovine ADA (the enzyme that corrects metabolic alterations). Furthermore, ADA-
gene transduced stem cells could not reconstitute the patient’s immune system (Blaese et al.,
1995; Kohn et al., 1998).
 Recently, Aiuti and colleagues treated ten children with SCID caused by ADA deficiency
with  ADA gene  therapy  and  all  patients  were  alive  after  a  median  follow-up of  4.0  years.
When they infused autologous CD34+ bone marrow cells transduced with a retroviral vector
containing the ADA gene, eight patients did not require enzyme-replacement therapy
anymore, their infused bone marrow cells continued to express ADA, and they had no signs
of defective detoxification of purine metabolites. Nine patients had immune reconstitution
with increased T-cell counts and normalization of T-cell function allowing normal life.
Serious adverse events related to ADA gene therapy and autologous bone marrow
transplantation included neutropenia, hypertension, central-venous-catheter-related
infections, Epstein-Barr virus reactivation and autoimmune hepatitis (Aiuti et al., 2009).
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4) Hematological diseases:
Sickle-cell disease is one of the most common hematologic monogenic disorders in the
world. Hemoglobin polymerisation, leading to erythrocyte rigidity and vascular occlusion, is
essential to the pathophysiology of this disease, although the importance of chronic anemia,
haemolysis and vasculopathy has been established (Rees et al., 2010). Lentivirus-mediated
gene transfer can correct hematological defects and organ damage in mice with sickle-cell
disease (Pawliuk et al., 2001).
5) Psychiatric disorders and addiction:
There is no indication that gene therapy can be used in the treatment of psychiatric patients
in  the  near  future.  Nevertheless,  there  are  several  promising  results  in  experimental
neuroscience. Gene therapy approaches have had an effect in animal models of several
psychiatric disorders including drug addiction, affective disorders, psychoses and dementia
(Thome et al., 2011). Carlezon and colleagues created a herpes simplex virus coding CREB
(adenosine 3?,5?-monophosphate response element binding protein) to reduce cocaine
addiction in rats. Cocaine regulates the transcription factor CREB in a region that is
important for addiction in rats. Overexpression of CREB in this region decreases the
rewarding effects of cocaine (Carlezon et al., 1998). Rosenberg and colleagues tested an
adeno-associated  virus  (AAV)  gene  transfer  vector  as  the  delivery  mechanism  of  an  anti-
cocaine monoclonal antibody (GNC92H2) in mice. Naïve mice exhibited hyperactivity
whereas AAV treated mice were completely resistant to the cocaine. This may provide a
new therapeutic option to treat cocaine addiction (Rosenberg et al., 2012).
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3. Adenovirus
3.1 Adenovirus structure
Adenoviruses are non-enveloped, double-stranded DNA viruses that belong to the family of
Adenoviridae. Adenoviruses have been characterized extensively since their initial description in
the early 1950s (Hilleman and Werner, 1954; Rowe et al., 1953). Based on their ability to
agglutinate human erythrocytes,  human adenoviruses are divided into seven species (A-G) and all
together 53 different serotypes have been identified so far (Smith et al., 2010). In this study we have
used adenovirus serotypes 5 and 3 that belong to the species C and B, respectively.
The geometric structure of adenovirus is an icosahedral with twelve protruding fibers from the
nucleocapsid corners (nucleocapsid diameter 80-100 nm) (Figure 2). The linear double-stranded
DNA inside the capsid is 36,000 base pairs long and the virus is relatively large, having a molecular
weight of ~150 MDa. The genome encodes more than 40 different proteins and 13 of these have
been shown to be constituents of the virus particle (Lehmberg et al., 1999; Russell, 2009; Stewart et
al., 1993). Within the core, the viral genome is condensed in association with proteins V, VII, and X
(or ?), and the 5? termini of the adenovirus DNA is covalently linked to the terminal protein.
Surrounding  the  core  is  a  capsid  composed  of  seven  proteins:  II,  III,  IIIa,  IV,  VI,  VIII,  and  IX
(Smith et al., 2010). Main viral capsid proteins are 240 units of hexons and 12 units of pentons.
Figure 2. Adenovirus structure. An adenovirus particle is composed of two major
structural elements, the outer capsid and the core. Main capsid and core proteins
(underlined) are shown. Modified from: (Russell, 2000).
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Table 2. Adenoviral particle proteins and their main functions. Core proteins underlined.
Protein Function References
Protease Core protein: necessary for production of the infectious virus
particle from the procapsid by cleaving the precursors to the
structural proteins IIIa, VI, VII, VIII, as well as pTP and precursor
of X
(Russell, 2009; Weber,
1976; Webster et al.,
1989)
Terminal protein Core protein: facilitate circularization of the virus genome, needed
in viral DNA replication
(Russell, 2009)
Protein II
 = Hexon
Major capsid protein: most abundant capsid protein (240 hexons in
the capsid), there are four kinds of hexons (H1, H2, H3 and H4)
based on their different environments
(Russell, 2009)
Protein III
 = Penton
Major capsid protein: RGD peptide on the penton base interacts
with cellular ???3/???5 integrins, thus facilitating virus
internalization and transport into endosomes for further processing
(Russell, 2009)
Protein IIIa Minor  capsid  protein:  associated  with  the  hexons  and  pentons  to
stabilize the virion capsid
(Saban et al., 2006)
Protein IV
= Fiber
Major capsid protein: the first virus component to interact with a
given tissue and target receptors
(Matthews and Russell,
1995; Russell, 2009)
Protein IVa2 Core protein: binds to DNA and is critical to the packaging process (Russell, 2009)
Protein V Core protein: provides a bridge between the core and the capsid (Russell, 2009)
Protein VI Minor capsid protein: associated with hexons and pentons to
stabilize the virion capsid, rupture the membrane of early
endosomes
(Saban et al., 2006;
Wiethoff et al., 2005)
Protein VII Core protein: highly basic and binds tightly to DNA, spreads along
the length of the virus DNA
(Russell, 2009)
Protein VIII Minor capsid protein: associated with hexons and pentons to
stabilize  the  virion  capsid,  VIII  provides  a  bond  between  the
peripentonal hexons and the rest of the capsid
(Russell, 2009; Saban et
al., 2006)
Protein IX Minor capsid protein: associated with hexons and pentons to
stabilize the virion capsid
(Saban et al., 2006)
Protein X (=µ) Core protein: has properties similar to those found in protamines (Russell, 2009)
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The complete sequence of adenovirus 5 has been published twenty years ago (Chroboczek et al.,
1992). The adenoviral genome contains five early transcriptional units (E1A, E1B, E2, E3 and E4),
three  delayed  units  or  intermediate  units  (IX,  IVa2  and  E2  late)  and  one  major  late  unit  that  are
processed into five late subunits (L1-L5) by alternative splicing (Figure 3). Early genes are
transcribed before viral DNA replication and late genes after DNA replication.
Figure 3. Schematic representation of the adenovirus genome, E = early genes,
L = late genes, MLP = major late promoter, LITR = left inverted terminal
repeats, RITR = right inverted terminal repeats and ? = packaging signal.
Packaging signal works as a start point for virus replication whereas inverted
terminals repeats are needed for complementary DNA pairing during virus
replication. Modified from: (Russell, 2000).
The early genes interfere with host cell defense mechanisms and are anti-apoptotic. They also alter
cell cycle and modulate cell functions to favor viral replication (e.g. synthesis of DNA-polymerase).
Late genes encode structural proteins and inverted terminal repeats are needed in DNA replication
where they act as primers. The adenovirus genome also contains viral associated RNAs (VA-
RNAs), which are required for efficient translation of viral mRNAs (Thimmappaya et al., 1982).
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Table 3. Adenoviral genes and their main functions.
Gene Function References
Early genes
E1A Primarily functioning in modulating cellular metabolism to make the cell
more susceptible to virus replication. Interferes with NF-?B and p53
thereby triggering entry into S phase of the cell cycle. E1A also binds to
Retinoblastoma (Rb) family members, releasing E2F transcription factor,
thus activating genes required for cell cycling. In addition, E1A proteins
inhibit activation of genes induced by IFN and IL-6 and may thus blunt
the effect of inflammatory cytokines.
(Anderson and Fennie,
1987; Berk, 2005; Reich
et al., 1988; Takeda et
al., 1994; Whyte et al.,
1988)
E1B E1B encodes two proteins: E1B-19k and E1B-55k. E1B-19K is
homologous in sequence and function to cellular BCL-2. BCL-2 family
proteins regulate apoptosis and have both pro-apoptotic and anti-apoptotic
proteins. E1B-19K binds to both BAK and BAX (both pro-apoptotic
BCL-2 family members), preventing them forming pores in the outer
mitochondrial membrane and thus preventing apoptosis. E1B-55K inhibits
the transcriptional activation of tumor suppressor protein p53.
(Cuconati and White,
2002; White, 2001; Yew
and Berk, 1992)
E2 The E2 gene products are subdivided into E2A and E2B. These provide
the machinery for replication of virus DNA and the following
transcription of late genes, and this is mediated by interaction with a
number of cellular factors. E2A encodes DNA-binding protein, which is
required  for  viral  DNA  replication  and  viral  DNA  is  synthesized  by  the
E2B DNA polymerase.
(Hay et al., 1995; Shenk
and Flint, 1991;
Weitzman and Ornelles,
2005)
E3 E3 gene products provide a compendium of proteins that subverts the host
defense mechanisms: (i) adenovirus death protein (ADP) facilitates late
cytolysis of the infected cell and thereby releases progeny virus more
efficiently, (ii) E3 gp19K is localized in the endoplasmic reticulum
membrane and binds the MHC class I heavy chain and prevents transport
to the cell surface, where it would be recognized by cytotoxic T-
lymphocytes (CTLs). E3 gp19K also inhibits expression of MHC class I
and (iii) some E3 proteins inhibit TNF apoptosis.
(Bennett et al., 1999;
Russell, 2000; Tollefson
et al., 1996)
E4 The gene products derived from the E4 cassette (termed orfs 1 – 6/7)
mainly facilitate virus mRNA metabolism (sometimes in association with
E1B gene products) and provide functions to promote virus DNA
replication and shut-off of host protein synthesis: orf1 facilitates
transformation, orf2 has unknown function, orf3 interacts with E1B 55k,
orf4 inhibits E1A activation of E2F, orf6 interacts with E1B 55k
facilitating RNA metabolism and orf6/7 modulates E2F activity.
(Goodrum and Ornelles,
1999; Halbert et al.,
1985; Russell, 2000;
Weigel and Dobbelstein,
2000)
Delayed / Intermediate genes
IX IX is a transcriptional activator and stimulates MLP. (Lutz et al., 1997)
IVa2 IVa2 plays a critical role in the transition from early to late phase and
controls the activation of MLP.
(Lutz and Kedinger,
1996)
Late genes
L1-L5 Encodes structural proteins (L2 penton, L3 hexon and L5 fiber) and
proteins for encapsulation and maturation of viral particles in the nucleus.
L4 100k protein blocks host translation and promotes viral translation.
(Russell, 2000;
Weitzman and Ornelles,
2005)
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3.2 Adenovirus transduction pathway and life-cycle
The adenovirus infectious cycle can be divided into two phases. The early phase in a permissive
cell  can  take  about  6  –  8  h,  while  the  late  phase  is  normally  more  rapid  lasting  4  –  6  h  (Russell,
2000). Typically the whole cycle is completed in 24 – 36 h.
The first or early phase:
? Entry of the virus into the host cell
? The passage of the virus genome to the nucleus, followed by the selective
transcription and translation of the early genes
The second or late phase:
? Transcription and translation of the late genes
? Production of structural proteins in the nucleus and the maturation of infectious
virus.
The fiber in the viral capsid is the first virus component to interact with the target tissue.  The
infection occurs via an aerosol transmission into the respiratory, gastrointestinal tract,
oropharyngeal or conjunctival epithelium (Russell, 2009). Adenoviruses utilize various receptors
(Zhang and Bergelson, 2005). The major receptor for most adenoviruses is the CAR receptor
(coxsackie adenovirus receptor), which is a member of the immunoglobulin superfamily and is
involved in vivo in the formation of tight junctions (Bergelson et al., 1997; Coyne and Bergelson,
2005; Coyne and Bergelson, 2006; Philipson and Pettersson, 2004). Adenoviruses from species A,
C,  E  and  F  interact  with  CAR receptors  while  species  B and  D utilize  other  receptors  e.g.  CD46
(Gaggar et al., 2005; Marttila et al., 2005; Segerman et al., 2003; Segerman et al., 2003; Sirena et
al., 2004), CD80 or CD86 (Marttila et al., 2005; Short et al., 2004), sialic acid receptors (Arnberg et
al., 2002; Segerman et al., 2003), heparin sulphate glycosaminoglycans (Dechecchi et al., 2001) or
desmoglein 2 (Wang et al., 2011).
The primary binding of viral fiber to CAR bends the fiber leading to interaction between cellular
?v?3 and ?v?5 integrins and a RGD peptide on the penton base (Mathias et al., 1998). This facilitates
virus internalization via clathrin-coated vesicles into endosomes, where viral capsid is disrupted
(Patterson and Russell, 1983). Interaction with integrins induces also a variety of cellular responses,
which are important in modifying the cytoskeletal structure in order to facilitate internalization (Li
et al., 1998a; Li et al., 1998b). Later, the endosomal membrane is disrupted and the virus attaches to
the nuclear pore complex, followed by DNA injection into the nucleus of the host cell (Berk et al.,
2007). The mechanism by which the virus genome is imported into the nuclear pore has been shown
to involve components of the nuclear pore complex (Greber et al., 1997) and CRM1, a nuclear
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factor exported from the nucleus (Strunze et al., 2005). Probably, the hexons are mostly shed at the
nuclear  pore  and  the  virus  core  enters  the  nucleus  (Matthews  and  Russell,  1998).  Thereafter,  the
viral DNA transcription and replication take place in the nucleus and viral proteins are produced in
the endoplasmic reticulum (ER) and transported back to nucleus, where viral particles are
assembled. The last the step of adenoviral life cycle occurs when new virions are released into
extracellular matrix after the cell lysis. The exact mechanism how adenoviruses trigger cell lysis is
still poorly understood (Figure 4).
Figure 4. Schematic representation of adenovirus transduction pathway and
life-cycle. Modified from: (Hakkarainen et al., 2005).
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3.3 Clinical manifestations of adenovirus infection
Adenoviruses typically cause mild infections in the upper or lower respiratory tract,
gastrointestinal tract, or conjunctiva (Lynch et al., 2011). Different serotypes display different tissue
tropism that correlates with clinical manifestations of the infection. Thus, for example species B, C
and E mainly cause respiratory disease, whereas species D induces ocular disease. Species F is
responsible for gastroenteritis and B2 viruses infect the kidneys and urinary tract (Russell, 2005).
The typical clinical manifestation is tonsillitis with cough, headache and fever. Spontaneous
recovery takes place usually within a week (Huovinen et al., 2007). Rare manifestations of
adenovirus infections include hemorrhagic cystitis, hepatitis, hemorrhagic colitis, pancreatitis,
nephritis, or encephalitis. Adenovirus infections are more common in young children due to
immature humoral immunity. Due to childhood exposure, pre-existing antibodies against
adenoviruses are very common in adults (e.g. 97 % seroprevalence for group C adenovirus) (Nayak
and Herzog, 2010). Epidemics of adenovirus infections may occur in healthy persons in closed or
crowded settings (e.g. military recruits) (Lynch et al., 2011). Infection routes include direct contact
through the respiratory or gastrointestinal tract, aerosol droplets, oral-fecal route and water (Russell,
2005). The disease is more severe and dissemination is more likely in patients with impaired
immunity (e.g. immunosuppressed patients having had an organ transplant). There are no specific
drugs against adenovirus infection, but Cidofovir is used for severe adenovirus infections (Lynch et
al., 2011). Vaccines have been shown to be very efficacious in reducing the risk of respiratory
infection but vaccines have not been available for some time because the only vaccine manufacturer
ended production in 1999 (Lynch et al., 2011; Potter et al., 2012). After a 12-year absence, the
adenovirus vaccination program for U.S. military recruits was resumed in October 2011 (Potter et
al., 2012).
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4. Adenoviruses for cancer gene therapy
4.1 A retrospect of oncolytic viruses
The use of viruses in the treatment of cancer resulted from observations that occasionally cancer
patients who were affected by an infectious disease went into short periods of clinical remission.
These early observations took place in the mid-1800s and in the beginning of 1900s. However, the
concept and nature of “virus” was totally unknown in medicine at that time (Kelly and Russell,
2007). Most of the patients whose tumor regression was seen simultaneously with natural virus
infection were suffering hematological diseases such as leukemia or lymphoma (Dock, 1904; Pelner
et al., 1958). Dock reported in 1896 of a 42-year old female with “myelogenous leukemia” who
went into remission after probable influenza infection.  It took 37 years to understand that influenza
is a viral disease (Kelly and Russell, 2007). In another case report, chicken pox led to regression of
lymphatic leukemia in a four year old boy (Bierman et al., 1953). After these early observations, it
took about half a century before more rational clinical testing started in the 1950s and 1960s (Table
4). Probably the major cause for this delay was the unclear identity and nature of viruses (Kelly and
Russell, 2007).
Because of limited success in the early clinical trials in 1950s and 1960s, many researchers
abandoned the concept for years. In the beginning of 1990s new DNA techniques brought viral
cancer therapy once again back to light. New DNA techniques made possible to modify viral
structure  and  make  them  more  specific  for  tumors,  reduce  undesired  adverse  events  and  still
maintain their natural potency to kill cancer cells (Kelly and Russell, 2007).
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Table 4. Four historically significant clinical trials related to oncolytic viruses. Modified from:
(Kelly and Russell, 2007)
Year Virus Experimental design Results Adverse
reactions
Reference
1949 Hepatitis B virus 22 patients with Hodgkin’s disease.
Treated with parenteral injection of
unpurified human serum and tissue
extracts
14/22 developed hepatitis,
7/22 improved in clinical
aspects of disease, 4/22
reduction in tumor size
Fever, malaise,
one confirmed
death
(Hoster et al.,
1949)
1952 Egypt 101 virus
(early passage
West Nile virus)
34 patients with advanced unresponsive
neoplastic disease.
Treated i.v. and i.m. injection of
bacteriologically sterile mouse brain, chick
embryo and human tissue.
27/34 infected, 14/34
oncotropism, 4/34 transient
tumor regression
Fever, malaise,
mild encephalitis
(2 confirmed)
(Southam and
Moore, 1952)
1956 Adenovirus
(adenoidal-
pharyngeal-
conjunctival virus
= APC)
30 patients with cervical cancer.
i.t., i.a. and i.v. injection of tissue culture
supernatant.
26/40 inoculations resulted
in local necrosis
Vaginal
bleeding,
infrequent fever
(3/30), malaise
(Georgiades et
al., 1959)
1974 Mumps virus
(wild type)
90 patients with various terminal cancers
(gastric, pulmonary, uterine > 50 %).
Administered: i.t., i.v., oral, rectal,
inhalation of purified human saliva or
tissue culture supernatant.
37/90 complete regression
or decrease > 50 %, 42/90 <
50 % decrease or growth
suppression, 11/90
progressive disease
Reactions for
7/90, bleeding,
fever
(Asada, 1974)
4.2 Modified adenoviruses
Adenoviruses can be modified by various ways to make them more suitable for the treatment of
human cancer. Possible ways of using adenoviruses in cancer treatment:
1) Viruses as vectors for functional genes:
Adenoviruses transport a functional gene into a target cell to replace the abnormal
dysfunctional gene. For example the p53-gene can induce apoptosis of cancer cells (Idema
et al., 2007).
2) Viruses as vectors for therapeutic genes:
Adenoviruses transport anti-angiogenic genes which prevents vascular system growth to
cancer cells (Zhang et al., 2005). Another option is to use genes that potentiate the effect of
other anti-cancer modalities like chemotherapy or radiotherapy.
3) Viruses as vectors for immunostimulation:
Adenoviruses transport GM-CSF (Cerullo et al., 2010) or IL genes (Lee et al., 2006), which
activate the human immune system and eventually eradicate the tumor.
4) Pro-drug therapy and suicide genes:
Adenoviruses transport Herpes simplex virus thymidine kinase (HSV-TK) into cancer cells,
which converts a harmless pro-drug to an active cytotoxic form in cancer cells, and
neighboring cancer cells are destroyed by the so-called bystander effect (Kirn et al., 2002).
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5) Oncolytic adenoviruses: the adenovirus genome is modified to replicate only in cancer cells
and the natural viral replication leads to cancer cell destruction (= oncolysis) (Bischoff et al.,
1996).
Approaches 1–4 are based on replication deficient adenoviruses and approach five utilizes
replicating adenoviruses. Wild type adenoviruses have many features that make them good tools for
cancer gene therapy, but there are also limitations:
Main advantages:
? Adenoviral genome and replication is well characterized
? Both the adenoviral genome and capsid are rather easy to modify
? Adenoviral structure and DNA is stable
? High viral titers (up to 1013 VP/ml) can be produced
? Adenoviruses infect both dividing and non-dividing cells
? Adenoviral DNA does not integrate into the host cell genome, resulting in low risk of
mutagenesis
? Adenovirus has a high transgene capacity (5.1 – 8.2 kbp)
Main limitations:
? Adenoviral gene expression is transient, which limits clinical use in diseases where long
lasting gene expression is crucial
? Natural liver tropism increases liver toxicity and decreases tumor transduction
? Low CAR expression in many tumors reduces tumor transduction
? Human immune system can detect and neutralize adenoviruses rather easily and also pre-
existing immunity and antibodies reduces the treatment efficacy
? Adenovirus storage in freezers (lower than -80 °C) and virus treatment preparations might
cause practical problems in hospitals because of limited infrastructure and personnel
expertise
Due to these limitations, wild-type adenoviruses have to be modified in order to increase tumor
transduction and gene expression, decrease liver tropism, and reduce immunogenity. Modifications
include both structural changes and viral genome remodeling.
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4.2.1 Replication deficient vectors
Replication deficient adenoviruses are used as gene transfer vectors. The capacity to carry foreign
DNA is, however, limited as the virus becomes unstable if the genome size exceeds 105 % of the
wild-type adenovirus (Bett et al., 1993). This led to development of so called first generation
adenoviruses where both E1 and E3 regions are deleted and E1 is often replaced with the desired
transgene (Hall et al., 2010). These vectors are replication deficient because limited replication
exists despite the absence of E1A (Imperiale et al., 1984). Unfortunately, these vectors induce
potent immune responses upon systemic application, limiting their clinical use (Hartman et al.,
2008; Muruve, 2004).
Second generation adenoviruses feature deletions in regions E2 or E4 in addition to deleted E1
and E3 regions. These vectors were designed to cause a milder host immune response and thus
prolonging transgene expression compared to first generation vectors (Hall et al., 2010). These
vectors also feature a higher capacity for transgenes. Adenovirus vectors with deleted E2 or E4 have
been constructed (Amalfitano et al., 1998; Dedieu et al., 1997), but it is unclear whether these
vectors are any better than first generation vectors since E2 mutation had no effect on the
persistence of transgene expression  (Engelhardt et al., 1994a; Engelhardt et al., 1994b; O'Neal et
al., 1998).
A significant advance in reducing immunogenicity and maximizing transgene capacity was taken
when helper-dependent adenovirus vectors were created. These third generation vectors are also
known as gutless vectors because all genes except the packaging signal and inverted terminal
repeats are removed (see Figure 3) (Fisher et al., 1996).
4.2.2 Replicating vectors
The efficacy of replication deficient adenoviruses in cancer therapy was low and data from clinical
trials was not satisfying (Rein et al., 2006). To address this problem, conditionally replicating
adenoviruses were created. In this approach, the therapeutic effect is not achieved only by transgene
expression but the natural viral replication per se causes the lysis of cells. However, these viruses
have to be targeted carefully to make sure that cell lysis takes place only in cancer cells (oncolysis)
but not in normal healthy cells. The transcriptional- and transductional targeting methods are
therefore applied (see section 4.3).
Replication also enables improved transgene expression leading to improved treatment efficacy. In
theory, selective replication in cancer cells leads to a situation where virus progeny will spread into
new neighboring cancer cells or metastases through the vascular system until all cancer cells are
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destroyed. Overall, treatment responses in cancer patients have been quite modest in clinical trials.
Thus, it may questionable if viral spreading really happens in vivo in physiological conditions.
Probably the most studied replicating oncolytic adenovirus is ONYX-015 (also known as dl1520),
which is an E1B deleted adenovirus targeted to replicate selectively in p53-deficient cancer cells
(Bischoff et al., 1996). However, later it became clear that ONYX-015 is not specific for p53-null
cells (Goodrum and Ornelles, 1998). The H101 virus is very similar to ONYX-015 but in addition
to the E1B-55k gene deletion it lacks all E3 proteins. H101 (or Oncorine) is one of the first
commercial adenovirus based cancer gene therapy products (see also section 4.3.2 and chapter 8)
and it was accepted for head and neck cancer therapy in China 2005 (Garber, 2006; Yu and Fang,
2007).
rAd-p53 (or Gendicine) is a recombinant replication-deficient adenovirus encoding human tumor
suppressor protein p53. It was the first approved cancer gene therapy product in China 2003 (Guo
and Xin, 2006).
4.3 Targeting of adenoviruses
Adenoviral targeting consists of various techniques that increase the viral selectivity of cancer
cells, reduce the tropism to normal tissues, hinder replication in normal tissues, decrease side
effects, and ultimately enhance the treatment efficacy and safety. Two approaches are currently
used (see Figure 5):
? Transductional targeting: the virus structure is modified so that viral entry to cancer cells
is more specific.
? Transcriptional targeting: the viral genome is modified so that viral replication and gene
expression occurs only in cancer cells.
4.3.1 Transductional targeting
As described in section 3.2, the importance of CAR in the transduction of many adenovirus
serotypes is well established; however, its role in humans is less clear (Hall et al., 2010).
Nevertheless, there is a considerable body of evidence indicating that CAR contributes to the uptake
of  adenovirus  species  C  (e.g.  Ad5)  and  therefore  its  expression  levels  in  tumors  need  to  be
considered when targeted vectors are designed (Hall et al., 2010). Unfortunately, the  expression of
CAR  is down-regulated in many cancers (Li et al., 1999; Okegawa et al., 2001; Rauen et al., 2002;
Wesseling et al., 2001a) and low CAR expression also correlates with poor prognosis and
aggressive disease (Matsumoto et al., 2005). There are at least four options to overcome this:
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1) Fiber pseudotyping:
In this approach the entire adenovirus knob is replaced with its structural counterpart from
another adenovirus serotype that binds a cellular receptor other than CAR. Krasnykh et al.
created the first adenovirus vector chimera that is based on adenovirus 5 but contains an
adenovirus 3 knob (Krasnykh et al., 1996). This Ad5/3 vector transduces cells in a CAR-
independent manner and has shown efficacy in preclinical models, as for example, in ovarian
cancer (Kanerva et al., 2002a) and in malignant glioma (Zheng et al., 2007).
2) Ligand incorporation:
While many cellular proteins are down-regulated during cancer progression, there is also up-
regulation of others, in particular specific cell-surface proteins (Hall et al., 2010). This creates
a possibility to exploit the up-regulated proteins by re-targeting adenoviral vectors by adding
novel attachment molecules (Nicklin et al., 2005). This can be done by adding a ligand into
the fiber knob without replacing the original knob. For example, incorporation of an RGD-
motif within the HI loop of the fiber knob redirects viral interactions towards cell surface
integrins and has shown encouraging preclinical results in malignant glioma (Tyler et al.,
2006) as well as in pancreatic cancer (Bilbao et al., 2002). Another example is to use the
polylysine motif (pk7) that binds heparan sulfate proteoglycans (HSPG) to enhance
transductional efficacy. In a preclinical malignant glioma model the Ad5-pk7 vector achieved
1000-fold increase in transgene expression compared to adenovirus without pk7 (Zheng et al.,
2007). However, this approach needs to be introduced with caution because HSPGs are
widely expressed also in normal cells.
3) Ligand incorporation to knobless viruses:
This approach arised from observations that fiber-deleted vectors could be produced
(Falgout and Ketner, 1988; Von Seggern et al., 1999). One example is an adenovirus, with a
knob replaced by human CD40-ligand, enhancing viral transduction into cancer cells where
CD40 is widely expressed (Belousova et al., 2003). In vivo systemic administration of this
virus resulted in hCD40 expression in the pulmonary vasculature of mice (Izumi et al., 2005).
4) Adapter molecules:
The utilization of adapter molecules in not exactly a “sub-category” for transductional
targeting because in this approach, the virus remains intact and adapter function is obtained by
molecules that cross-link the adenovirus and a specific cell surface structure. However, it is
presented here because the goal to improve transduction is the same as in approaches 1–3.
This approach also includes new challenges due to the adapter molecule because its effects in
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host organs should be studied first and finally the effects of this two-component combination
together. This concept was first published by Douglas et al. The folate receptor was targeted
by an adenovirus with a folate ligand chemically conjugated to an anti-fiber antibody
(Douglas et al., 1996). The folate receptor is over-expressed on the surface of a variety of
malignant cells, which also makes this approach appealing.
4.3.2 Transcriptional targeting
To achieve adenoviral replication and gene expression selectivity to cancer cells, transcriptional
targeting can be employed. Two approaches are widely used: targeting via genetic deletions or
utilization of tumor specific promoters.
1) Targeting via genetic deletions (Type I adenoviruses):
In this approach the tumor targeting is achieved by deleting E1A or E1B regions from the
adenovirus. The virus cannot replicate in normal cells in the absence of E1A or E1B, but these
deletions are compensated by the carcinogenic mutations in cancer cells leading to cancer cell
specific replication.
The prototype for transcriptionally targeted adenovirus is previously mentioned ONYX-015
(see section 4.2.2). ONYX-015 has deletions in the gene coding E1B-55k which inhibits
tumor suppressor gene p53 allowing ONYX-015 to replicate selectively in p53-deficient
cancer cells (Bischoff et al., 1996; White, 2001; Yew and Berk, 1992). p53 is a tumor
suppressor protein that has a central role in cell cycle control and its dysfunction is related to
most cancers (Kumar et al., 2008). p53 receives inputs from cell stress and abnormality
sensors; if the degree of damage to the genome is excessive, p53 stops cell cycle progression
until damages are repaired or it triggers apoptosis if damages are too severe to be repaired
(Hanahan and Weinberg, 2011). ONYX-015 showed specific replication in p53 mutated cells
(Heise et al., 2000; Heise et al., 1999), but the E1B-55k deletion also partly disrupted the
cancer  cell  killing  potential  (Dix  et  al.,  2001).  Also,  some  cells  with  normal  p53  were
permissive for ONYX-015 replication (Goodrum and Ornelles, 1998).
An alternative strategy to create a replicating oncolytic adenovirus is to delete 24 bps in the
constant  region  2  of  E1A.  As  described  earlier  (see  section  3.1),  products  of  the  E1A gene
bind to the cellular retinoblastoma protein (Rb), which leads to displacement of the E2F
transcription factor (Whyte et al., 1988). The released E2F further transactivates genes
responsible for entry into S phase (Whyte et al., 1988). An adenovirus with the 24 bp deletion
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does not inactivate Rb and is therefore able to replicate only in cells with a defective Rb
pathway. A defective Rb pathway is common in most cancers (Sherr, 1996).
2) Tumor specific promoters (Type II adenoviruses):
Tumor specific promoters (TSPs) can be used to control viral gene expression and limit the
expression in cancer cells (Table 5).
Table 5. Selected tumor specific promoters (TSP) and target cancers.
TSP Type of cancer Results Reference
PSA
Prostate specific
antigen
Prostate cancer PSA was inserted to drive E1A
expression. CN706 virus destroyed large
tumors and abolished PSA production in
mice.
(Rodriguez et
al., 1997)
CEA
Carcinoembryonic
antigen
Colorectal cancer with
liver metastases
CEA promoter-dependent tk gene
expression led to significant tumor size
reduction in mice without side effects in
liver.
(Brand et al.,
1998)
?-fetoprotein Hepatic cancer E1B55k-deficient adenovirus carrying
E1A and attenuated E1B gene driven by
the alpha-fetoprotein promoter (Adv-
AFP-E1AdB) reduced mouse liver
tumors.
(Ohashi et al.,
2001)
Chromogranin A Neuroendocrine cancer Chromogranin A promoter controls the
E1A gene. Ad[CgA-E1A] virus was able
to suppress fast-growing human
carcinoid tumors in mice.
(Leja et al.,
2007)
There are also ubiquitous promoters that take advantage of regulatory elements common in
most tumor cells. Compared to conventional TSPs, ubiquitous promoters are active in various
cancer types making them more applicable for viral cancer gene therapy. The cyclo-
oxygenase 2 (Cox-2) promoter (Wesseling et al., 2001b), E2F-promoter (Tsukuda et al.,
2002) and hypoxia response element (HRE) (Binley et al., 2003) are examples of ubiquitous
promoters.
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4.4 Blood factors and adenovirus biodistribution
The transductional targeting concept is based on the idea that adenovirus biodistribution is mostly
determined by receptor distribution. However, adenovirus serotype 5 biodistribution in animals
does not directly correlate with the expression of adenovirus receptors (e.g. CAR). Significant
levels of liver transduction occur in mouse models after systemic delivery of the virus (Fechner et
al., 1999; Lieber et al., 1997; Shayakhmetov et al., 2004). This can lead to liver toxicity (Young and
Mautner, 2001). Intravenous delivery is very common in gene therapy trials, although dissemination
of adenoviruses to the bloodstream is very rare in nature (Hall et al., 2010).
It has been demonstrated that liver transduction occurs independently of CAR (Alemany and
Curiel, 2001; Martin et al., 2003). Blood coagulation factors like factor IX and complement
component C4 binding protein have been proposed to bind to the adenovirus surface and form a
bridge from Ad5 to the HSPGs and low-density lipoprotein related-receptor proteins of hepatocytes
(Hall et al., 2010). Also additional vitamin K-dependent blood factors (Factor X and VII, protein C)
may enhance virus transduction in hepatocytes (Parker et al., 2006). This also gives an opportunity
to decrease liver transduction by reducing vitamin K-dependent zymogens with warfarin treatment,
leading to lower liver toxicity (Parker et al., 2006). Controversial data exist on the interaction of
fiber proteins and coagulation factors: reduced liver transduction was shown with short shaft-
containing fibers (Ni et al., 2005; Schoggins et al., 2003; Shayakhmetov et al., 2005), but fiberless
virus interacted with Factor X similarly as wild-type virus questioning the involvement of fiber
proteins (Waddington et al., 2008).  Waddington et al also demonstrated that the major binding site
for Factor X on the Ad5 capsid is the hexon and that this interaction required calcium (Waddington
et al., 2008).
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Figure 5. Simplified schematic representation of the main principles of targeted oncolytic
adenoviruses in cancer gene therapy.
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5. Adenoviruses and radiotherapy
5.1 Introduction to radiotherapy
Many historical landmarks in medicine cannot be dated exactly, but radiotherapy makes an
exception. The first treatment with external radiation was given on the 29th of January 1896 in
Chicago when a patient with breast cancer was treated (Holsti, 1995). This took place only one year
after the discovery of X-rays by Wilhelm Conrad Röntgen. The Nobel Prize in physics in 1901 was
awarded to Röntgen “in recognition of the extraordinary services he has rendered by the discovery
of the remarkable rays subsequently named after him" (www.nobelprize.org., 2012). However,
Röntgen himself was not very interested in the biological effects of X-rays.
The first treatment in Finland was given to a sarcoma patient in 1903 in Helsinki (Lahtinen and
Holsti, 1997). Since then, remarkable improvements have taken place and modern radiotherapy
provides precise techniques to treat successfully various cancer types by using, for example,
intensity modulated techniques and arc therapies linked to image-guidance. In addition to more
conventional therapies, brachytherapy, boron neutron capture therapy (BNCT) and proton therapy
are also used in modern radiation oncology.
5.2 Principles of radiotherapy
The effect of radiotherapy in biology is based on its ability to damage vital cellular components
such as DNA or cell membranes. The radiosensitivity varies in different tissues making some
tumors more resistant to the effects of radiation, but radiosensitivity can also vary between different
cells within the same tumor. The radiosensitivity and -response is the most important factor
defining the effect of radiotherapy and it is based on four main principles. Reoxygenation due to
neo-angiogenesis in tumors repairs hypoxia and oxygen potentiates the radiotherapy response.
Repair of sub lethal damages in DNA can be repaired more successfully in healthy tissues
compared to tumors between fractions. Radiation damage initiates repopulation where dead cells
are replaced with new ones. Repopulation seems to be more effective in healthy tissues. Cells are
also redistributed in the cell cycle, rapidly dividing cancer cells are more likely to be in the
radiosensitive phase (M-phase or late G1- and late G2-phases).
Radiation can damage biological material directly (~30 % of the effect) or indirectly (~70 % of the
effect) via radiolysis of water producing reactive oxygen species (ROS). Double strand breaks are
lethal to cells but also single strand breaks can be lethal if two such breaks exist simultaneously in
close proximity of one another (Lahtinen and Holsti, 1997). ROS oxidise cell membrane
phospholipids and fatty acids, which are then hydrolyzed by a number of enzymes (Haimovitz-
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Friedman et al., 1994; Hallahan et al., 1994). These enzymes also activate second messengers and
further cascades of enzymes within the cytoplasm, typically kinases that can either down- or up-
regulate gene expression (Hallahan, 1996). Cell death after radiation therapy occurs by at least three
mechanisms: apoptosis, postmitotic cell death and/or necrosis. Apoptosis and postmitotic cell death
occurs early, whereas necrosis is a late effect of radiation (Hallahan, 1996). Radiation has a variety
of effects on genes that regulate cell proliferation, tissue regeneration, production of cytokines and
growth factors, formation of fibrotic tissue, vascular damage response, cell death, radioresistance,
cell cycle regulation, signal transduction, and transcription factors (Hallahan, 1996). As radiation
damage does not separate normal cells and tumor cells, clinical radiotherapy is a continuous
balancing act between tumor control and normal tissue complications. This is a complex endeavor,
since the radiotolerance of specific tissues in the body depends on the volume irradiated, total
delivered dose, the dose per fraction and the level of acceptable risk (Regine, 2002). Traditionally it
has been thought that radiotherapy is a local treatment, so it cannot eradicate and target tumor cells
that are outside of the treatment fields or that have metastasized to sites beyond the primary tumor.
Nevertheless, there is also evidence indicating that radiotherapy might feature an abscopal effect in
which local radiotherapy regress distant metastatic non-radiated tumors via immunological
activation (Postow et al., 2012).
Figure 6 summarizes the principle of immediate physical DNA damage due to radiotherapy. The
total effect of radiation, however, depends significantly on many other processes as well and overall
effects can occur many years later and depend on various complex biochemical and biological
mechanisms that are not discussed in detail here.
43
Figure 6. Upper panel: An example of an external radiotherapy plan for prostate cancer is shown
(transversal CT-image view). In brief, the plan consists of two lateral fields from both sides of the
patient and one anterior arc field. In the middle (marked with red outline) is the prostate where the
radiation dose is maximal (~ 74 Gy) indicated by the red color. Dose is minimized in surrounding
healthy tissues (rectum, bladder and pelvic joints) indicated by green and blue colors.
Lower panel: Schematic representation of the radiation damage to DNA. Radiation damage in
tissues is mostly based on the radiolysis of water and the formation of free radicals that interact with
DNA. Lethal DNA damage in cancer cells leads to tumor size reduction, whereas in normal cells it
may lead to toxicity.
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5.3 Combination of adenoviruses and radiotherapy
The combination of radiotherapy and oncolytic adenoviruses is appealing for many reasons.
Oncolytic adenoviruses can increase the effect of radiotherapy in a synergistic manner by increasing
overall cancer cell killing. Radiotherapy can also increase the expression of therapeutic transgenes
from adenoviral vectors and the combination is synergistic in many cases due to the non-
overlapping mechanisms of action. Furthermore, the combination does not increase severe adverse
events due to the non-overlapping side-effect profile, but the overall number of adverse events
might be higher. Finally, both treatments can be applied to various types of cancer.
Several promising trials combining adenovirus-p53 with radiotherapy confirmed the utility of the
approach in both head-and-neck cancer and lung cancer (Pan et al., 2009; Swisher et al., 2003). In
randomized controlled trials, radiation combined with AdvHSV-tk (adenoviral vector encoding the
HSV  thymidine  kinase  gene)  increased  the  survival  of  patients  with  glioma  or  hepatocellular
carcinoma (Immonen et al., 2004; Li et al., 2007; Yla-Herttuala, 2008). According to one theory,
E1A  proteins  could  sensitize  carcinoma  cells  to  radiation  (Sanchez-Prieto  et  al.,  1996),  but  also
E1A deleted viruses have shown anti-tumor efficacy with radiation (Lamfers et al., 2002), explained
by the fact that not only E1 proteins but also E4 proteins have radiosensitizing features.
The cellular DNA damage repair has been recently linked to these synergy effects. Double strand
breaks in DNA can result from exposure to agents such as ionizing radiation and carcinogenic
substances, but might be also generated from endogenous sources like meiotic recombination.
Mammalian cells have two main pathways for DNA double strand break repair: homologous
recombination and non-homologous end-joining (Weitzman et al., 2004). From the DNA damage
repair machinery point of view, the double strand DNA breaks and adenoviral double stranded
DNA genomes are both perceived similarly.
At late times of infection, amplification of the adenovirus genome presents the cell with as many
as 100,000 double stranded DNA ends (Weitzman and Ornelles, 2005). These ends can be sensed as
double strand breaks and the host cell responds to this by activating cellular DNA repair machinery
(Carson et al., 2003; Stracker et al., 2002). However, it has been shown that only infection with an
adenovirus lacking the E4 region induces this cellular DNA damage response forming concatemers
of viral DNA, but wild-type virus blocks this signaling through degradation of the Mre11 by the
viral E1B55K/E4orf6 proteins (Carson et al., 2003). This suggests that one of the many functions of
DNA damage repair machinery is to form an obstacle for wild-type virus infection and especially
E4 proteins have a significant role by counteracting this (Weitzman and Ornelles, 2005).
The MRN complex is a key player in the cellular response to DNA damage and recognition of
double stranded DNA breaks. The MRN complex contains Mre11, Rad50 and NBS1 proteins
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(Stracker et al., 2002). ATM and ATR signal cascades relay the message down-stream of the MRN
complex by protein phosphorylation and this signal cascade is also activated during E4 deleted
adenovirus infection (Carson et al., 2003). Many cellular DNA repair and checkpoint proteins (e.g.
Chk1, Chk2, 53BP1, H2AX, BRCA1, p53 and RPA32) are also substrates for ATM and ATR
kinase activity (Kastan and Lim, 2000; Shiloh, 2003).
The E4 region of the virus and especially E4orf3 and E4orf6 are central  regulators of the MRN
complex. E4orf3 associates with the nuclear matrix and induces the reorganization of nuclear bodies
called PML oncogenic domains (PODs) and nuclear domain 10 (ND10) (Doucas et al., 1996).
These are large nuclear structures featuring a variety of functions like maintaining genomic
stability, repairing DNA damage, controlling transcription and controlling both apoptosis and IFN
response (Borden, 2002). E4orf3 rearrange the PODs by an unknown mechanism and this favors
viral replication (Maul, 1998). E4orf6 forms a complex with E1B55k protein, and this complex is
involved in viral DNA replication, RNA processing and hindering of host protein synthesis
(Weitzman and Ornelles, 2005). There is a redundancy between E4orf3 and E4orf6 proteins for
their ability to prevent concatemerization and this is achieved by targeting Mre11. E4orf3
mislocalizes Mre11 whereas the E1B55k/E4orf6 complex degrades Mre11 (Stracker et al., 2002).
Mre11 degradation by oncolytic adenoviruses is associated also with increased autophagy and the
effect was enhanced when viral treatment was combined with radiation (Rajecki et al., 2009).
E4orf6 protein may also radiosensitize cells independently of E1B55k and Mre11 (Hart et al.,
2005). There is also evidence that both E4orf3 and E4orf6 increase cancer cell killing in vivo when
transgenically expressed and combined with radiotherapy, making this approach attractive
(Liikanen et al., 2010). Both E4orf6 and EIB55k can also independently inhibit the transcriptional
activity of p53 and therefore p53 functions in cellular DNA damage are inactivated during viral
infection (Cathomen and Weitzman, 2000; Yew and Berk, 1992).
Taken together, the precise reasons for synergy between adenoviruses and radiotherapy are still
mostly unknown but the above mentioned aspects are involved. The degradation of the MRN
complex by the viral E1B55k/E4orf6 proteins abrogates ATM activation by auto-phosphorylation
and subsequent signaling in response to DNA damaging agents like radiation (Weitzman et al.,
2004). This contributes to the synergy at least to some extent. Radiation also enhances transgene
expression from adenoviral vectors. At a late time point of adenovirus infection, products from the
E4 region block the host cell gene expression and in association with E1B55k, E4orf6 directly
prevents nuclear export of cellular mRNA (Dobner and Kzhyshkowska, 2001). When promoting
late gene expression, the E1B55k/E4orf6 complex and E4orf3 proteins indirectly hinder host cell
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gene expression by increasing the expression of 100k protein from L4, which in turn blocks host
translation while promoting late viral gene translation (Weitzman and Ornelles, 2005).
In addition to the link between radiation induced DNA damage and adenovirus DNA breaks repair
inhibition, there are many other mechanisms that might contribute to the synergy. Radiotherapy has
been shown to enhance T-cell trafficking, antigen presentation, and T-cell recognition of tumor
cells (Lugade et al., 2005; Reits et al., 2006). This suggests that radiation can increase both the
generation of antitumor immune effector cells and their trafficking to the tumor site, which might
have a positive impact for immunovirotherapy. However, like many forms of cancer therapies, also
radiotherapy can be locally immunosuppressive, killing lymphocytes, and the optimal combination
to improve antitumor immune responses will require careful consideration (Prestwich et al., 2008).
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6. Immune responses in adenoviral infection and cancer therapy
6.1 Host responses to adenovirus infection
Immunity refers to the protection against infectious agents and the immune system is a very
delicate collection of cells and molecules that perform this task. Deficiencies in the immune system
can lead to various common diseases such as allergies, bronchial asthma, insulin-dependent diabetes
mellitus, inflammatory bowel disease, rheumatoid arthritis and malignancies. Also in cancer,
immune system functions are compromised allowing tumor growth and metastasis.
The human immune system consists of innate (or natural) immunity and adaptive (or acquired)
immunity. Innate immunity is mostly mediated by cells that are always present in body and are
called into action immediately in response to infection, but also immunologically inactive cells such
as epithelial cells in the respiratory tract can produce anti-inflammatory agents in infection (e.g.
Type I interferons in viral infection). The major components of innate immunity are: epithelial
barriers, phagocytic leukocytes (neutrophils and macrophages), natural killer (NK) cells and the
complement system. The response of innate immunity is fast but less specific.
Adaptive immunity is more powerful against infectious agents due to its ability to adapt, expand
and generate potent, more specific mechanisms to eliminate harmful subjects. The major types and
components of adaptive immunity are: humoral immunity created by B-lymphocytes that produce
soluble antibody proteins and cell-mediated (or cellular) immunity generated by T-lymphocytes
(Kumar et al., 2008).
The understanding of the immune response to adenovirus infection in cancer gene therapy is
crucial for three reasons: the rapid clearance of adenoviruses by immunological defense
mechanisms decreases the treatment efficacy (Otake et al., 1998; Worgall et al., 1997), the strong
immune response to infection might cause severe life-threatening adverse events (Raper et al.,
2003), and adenovirus induced immune response can be used for therapeutic benefit in
immunovirotherapy. Several aspects of modified adenovirus biology (e.g. genomic deletions and
capsid modifications) differ from the biology of wild-type adenovirus infection, therefore the
knowledge of wild-type adenovirus biology cannot always be directly applied to adenoviruses used
in cancer gene therapy (Muruve, 2004). The roles of both innate immunity and adaptive immunity
to adenovirus infection are discussed below.
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6.1.1 Innate immunity in adenovirus infection
The first line of defense against adenovirus infection in nature is epithelial cells in respiratory- and
gastrointestinal tracts. However, in the context of cancer gene therapy, where adenoviruses are often
administered through the intravascular route, the endothelial cells of blood vessels perform this
same function, but in nature this situation is rare and less is known how adenoviruses are able to
penetrate the endothelial lining. Mechanisms after intratumoral injection are also poorly understood.
Adenoviruses induce innate immunity response shortly after transduction. This innate early
response occurs as a result of the interaction of the virus with the cell and does not depend on the
transcription of viral genes (Russell, 2009). It is been confirmed that interaction of the viral capsid
with the host cell is sufficient to activate inflammatory responses (Muruve, 2004). There is also
evidence that adenovirus elimination takes place in two phases at least in the liver, where the early
phase is mediated by innate immunity and is the dominant mechanism resulting in a 90 % loss of
vector DNA during the first 24 hours after infection (Worgall et al., 1997).
The first task of innate immunity is to recognize the virus, which occurs via the nucleotide-binding
oligomerization domain/leucine-rich repeat (NOD-LRR) family of proteins and pathogen-associated
molecular patterns (PAMPs) using pattern-recognition receptors (PRRs) (Muruve, 2004). The best-
described PRR is the Toll-like receptor (TLR) family. The most important TLRs in adenovirus
infection are TLR2 on the cell surface, and TLR9 in endosomes (Appledorn et al., 2008; Cerullo et
al., 2007). TLR9 recognizes unmethylated CpG sequences in any DNA including adenoviral DNA,
and it may be that the adenovirus genome is sufficiently different from the methylated CpG seen in
normal  cell  DNA  to  signal  that  foreign  DNA  is  present  (Cerullo  et  al.,  2007).  Virus  recognition
activates adaptor proteins including MyD88, TRIF and TRAF6 (Akira, 2006), leading to signal
transduction via mitogen-activated protein kinases (MAPKs) and finally to the activation of NF-?B
and  the  transcription  of  host  cytokine  genes  (e.g.  IL-5,  IL-6,  IL-8,  IL-12,  TNF-alpha,  RANTES,
MIP-2) and type I interferons (Girardin et al., 2002; Inohara and Nunez, 2003). This cytokine
response controls the infection locally and recruits granulocytes, NK-cells, macrophages to perform
cytolytic function and secrete more cytokines to amplify the immune response (Muruve, 2004).
Viral antigen presentation of macrophages via class I MHC molecules to CD8+ T-cells is essential
for the development of adaptive immunity (Kumar et al., 2008). The complete clearance of
intracellular viruses depends on the destruction of infected cells by the effector cells from innate
immunity (NK-cells) and adaptive immunity (CD8+ T-cells), but much of the antiviral potential of
these  cells  also  reflects  their  ability  to  produce  antiviral  cytokines  such  as  IFN-gamma and  TNF-
alpha at the site of the infection (Guidotti and Chisari, 2001). Furthermore, IFN-gamma secretion is
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important in the development of helper T-cell type I adaptive immune response (Taniguchi et al.,
2003).
Taken together, structural components of the virus, both capsid and DNA, play various roles in the
induction of the innate immune response to adenovirus infection, and outcomes can vary depending
on the virus species and the nature of the infected cell (Russell, 2009).
6.1.2 Adaptive immunity in adenovirus infection
The expression of proinflammatory mediators upon adenovirus infection occurs before significant
viral gene transcription, suggesting that the adenovirus capsid triggers this response (Muruve,
2004). After intravenous administration, adenoviruses produce a biphasic production of cytokines:
the first course corresponds to innate immunity during the first 24 h and happens with first-
generation, helper-dependent and inactivated adenoviruses, whereas the second course corresponds
to adaptive immunity after 4-5 days and it depends on viral gene expression (Liu et al., 2000;
Muruve, 2004). Thus, the second peak is not seen with helper-dependent or inactivated
adenoviruses. Nevertheless, the adenovirus particle per se is sufficient to trigger an adaptive
immune response without gene transcription inducing adenovirus specific cytotoxic T-lymphocytes
(Kafri et al., 1998; Roth et al., 2002).
All nucleated cells express class I MHC molecules on cell surface and display viral antigens to T-
cells, thus all virus-infected cells can be detected and eliminated by cytotoxic T-cells (Kumar et al.,
2008). However, a resting T-cell needs co-stimulatory signals for full activation and these signals
come  from  a  dendritic  cell  when  a  T-cell´s  CD28-molecule  binds  to  the  B7-molecule  on  the
dendritic cell (Arstila, 2007). Only dendritic cells are able to induce the sleeping T-cell response.
Unlike in class I, the tissue distribution of class II MHC expressing cells is quite restricted, they are
constitutively expressed mainly on antigen presenting cells (APC) such as macrophages, dendritic
cells  and  B-cells.  Class  II  MHC displays  antigens  derived  from protein  synthesis  outside  the  cell
and present these antigens to CD4+ helper  T-cells  activating  them (Kumar  et  al.,  2008).  Also,  B-
cells  need  two signals  for  activation,  the  first  comes  from antigen  and  the  second comes  from T-
cells  that  also  produce  crucial  cytokines  for  B-cells  maturation.  Finally,  the  process  that  was
initiated by dendritic cells turns into dialogue between T- and B-cells, which supports both T- and
B-cell activation, maturation and function (Arstila, 2007). A complex set of interactions between
the innate and the adaptive immune system results in the activation of CD4+ and CD8+ T-cells and
B-cells (Seiler et al., 2007). T- and B-cells also create a memory after primary infection, which is
long-lasting and consequently, response to re-infection is faster and more specific.
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6.2 Cancer immunology
It was thought that the immune system constantly searches and destroys pre-malignant cells in the
body in the absence of external therapeutic intervention and thus prevents the formation of
malignant clinical tumors. This concept is more than 100 years old and was presented by Nobel
Laureate Paul Ehrlich 1909 (Dunn et al., 2004). This theory is partly controversial, because cancer
cells originate anyway from the human´s normal cell populations and because of this, the immune
response against these cells is more or less inadequate for tumor eradication. However, tumors have
structures that could wake up the immune system, such as mutated proteins encoded by oncogenes
or malignant transformation associated proteins. There is also clear evidence that the immune
response can improve the prognosis of cancer patients. This is supported by the historical evidence
of viral infections (see section 4.1), but probably the most profound piece of evidence is the so-
called “graft-versus-leukemia” phenomena, where transplanted allogenic stem cells can destroy
remaining leukemia cells and prevent the relapse (Kolb, 2008). It is essential to gain an efficient
immune response towards tumors and for most cancers this is not currently possible. Monoclonal
antibodies provide one approach to overcome this limitation and many immunotherapies have been
approved for cancer (Finn, 2008). Table 6 shows some currently available immunotherapy agents
that are approved by the Food and Drug Administration (FDA).
The original concept described by Erhlich was difficult to study, but later when the field of
immunology developed and experimental testing became possible, the concept acquired a new
name “immunosurveillance” (Burnet, 1970). Most recently, it has been proposed that the immune
system not only protects the host against tumor development but also, by selecting for tumors of
lower immunogenicity, has the capacity to promote tumor growth. These dual effects have refined
the term “immunosurveillance” into “immunoediting” (Dunn et al., 2002). There are three
cornerstones in the concept that are denoted the ‘three Es’ of cancer immunoediting (Dunn et al.,
2004). In the first Elimination phase the immune system tries to eradicate the developing tumor. If
this happens successfully it represents the complete immunoediting process without progression to
the subsequent phases. In the second Equilibrium phase the host immune system and any tumor cell
variant that has survived the elimination phase enters into a dynamic equilibrium, where Darwinian
selection takes place: the “best” cancer cell variants carry mutations which make them resistant to
immune attack. This is probably the longest phase. In the final Escape phase tumor cell variants
selected in the equilibrium phase now can grow in an immunologically intact environment.
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Table 6. Current clinically approved immunotherapy treatments and prophylactic vaccines.
Modified from: (Finn, 2008; Mellman et al., 2011)
Treatment Indication Principle of action or type of therapy
Allogenic bone marrow
transplantation
leukemias and lymphomas The graft-versus-leukemia effects involve the
direct killing of tumor cells by donor
lymphocytes, together with the subsequent
induction of broader innate and adaptive
reactions
Prophylactic vaccines
Inactivated HBV antigen
(e.g. Engerix-B)
HPV serotype proteins
(Cervarix, Gardasil)
Hepatic cancer
Cervix cancers
Prevention of cancers of viral origin: prevention
of hepatitis B virus and human papilloma virus
infection, respectively
Cell based therapies
sipuleucel-T (Provenge) Advanced prostate cancer Comprises an incompletely characterized,
complex mixture of peripheral blood
mononuclear cells supplemented with a cytokine
and tumor-derived differentiation antigen
Monoclonal antibodies
Generally: antagonizing oncogenic pathways,
opsonizing tumor cells, triggering antibody-
dependent cellular cytotoxicity or phagocytosis,
apoptosis induction
Trastuzumab Breast cancer, gastric cancer Her2-receptor
Panitumumab Colorectal cancer with wild-
type KRAS
Her1-receptor
Cetuximab Colorectal cancer, Head & Neck
cancer
epidermal growth factor receptor
Bevacizumab NSCLC, colorectal and breast
cancer
vascular endothelial growth factor receptor
Rituximab,
Ibritumomab tiuxetan,
Tositumomab)
Non-Hodgkin´s B-cell
lymphoma
CD20 B-cell surface antigen
Ofatumumab Chronic lymphocytic leukemia CD20 B-cell surface antigen
Brentuximab vedotin Hodgkin´s lymphoma CD30 cell surface antigen
Gemtuzumab ozogamicin Acute myeloid leukemia CD33 leukemic-cell surface antigen
Alemtuzumab Chronic lymphocytic leukemia
and T-cell lymphoma
CD52 lymphocyte surface antigen
Ibilimumab Melanoma CTLA2 antagonist which leads to T-cell
activation
Cytokines/Other
Aldesleukin Melanoma and renal cancers interleukin-2 analogue
IFN-? (Intron A, Roferon-A) Various cancers Recombinant interferon
TLR7 (Imiquimod) Basal-cell carcinoma Toll-like receptor 7 agonist
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The immune system can respond to cancer cells in two ways: by reacting against tumor-specific
antigens (molecules that are unique to cancer cells) or against tumor-associated antigens (molecules
that are expressed differently by cancer cells and normal cells) (Graziano and Finn, 2005). Tumors
counteract by suppressing immunity both systematically and in the microenvironment (Figure 7)
(Rabinovich et al., 2007). Tumors have various strategies to produce an immunosuppressive
environment that favors the growth of tumors. Tumors can produce immunosuppressive molecules
such as TGF-? that induces helper and cytotoxic T-cell arrest, inhibits T-cell effector functions
(cytotoxicity and IFN-? production) and recruits/differentiates CD4+ T-cells into T-regs to induce
tolerance (Teicher, 2007). They can also produce soluble Fas-ligand that binds to Fas-receptor on
effector T-cells to trigger apoptosis (Houston et al., 2003). Tumors secrete immunosuppressive
enzyme indolamine-2,3-dioxygenase (IDO) to catabolize tryptophan and cause T-cell anergy
through tryptophan depletion (Muller and Prendergast, 2007; Uyttenhove et al., 2003). Tumor cells
inhibit MHC-I, and peptide processing and loading on MHC-I to produce suboptimal antigen
exposure (Alemany and Cascallo, 2009).
An increase in regulatory T-cells has been observed in the peripheral blood of patients with head
and neck cancer, showing that immunosuppression can be also systemic (Chikamatsu et al., 2007).
Patients with colorectal cancer and pancreatic cancer have increased numbers of activated
granulocytes (Schmielau and Finn, 2001) and myeloid-derived suppressor cells (Nagaraj and
Gabrilovich, 2007), both of which suppress tumor-specific T-cells. Overall, the balance between the
immunostimulatory and immunosuppressive forces both at the systemic and microenvironment
level will determine whether the tumor can grow and progress, or not. Tumor-induced
immunosuppression favors malignant tumor formation (Figure 7).
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Figure 7. Immunostimulatory and immunosuppressive forces in the tumor microenvironment. A
growing tumor secretes both immunostimulatory and immunosuppressive antigens that attract
dendritic cells.
Left part (immunostimulation): Dendritic cells take up tumor antigens, mature into IL-12 producing
cells, and in the lymph nodes stimulate Th1-type CD4+ T-cells that produce IFN-?. These cells help
expand the population of CD8+ cytotoxic  T-lymphocytes  that  can  destroy  tumor  cells  through
effector molecules granzyme B and perforin.
Right part (immunosuppression): Another set of tumor antigens promote maturation of a different
type of dendritic cell that makes IL-6 and TNF-? and give rise to Th2-type CD4+ T-cells. Those
cells make IL-4 and IL-13 and are not effective in tumor rejection. This immunosuppressive
environment also promotes generation of regulatory T-cells and macrophages and myeloid-derived
suppressor cells (MDSC). At the time the tumor is diagnosed, the balance between the stimulatory
and suppressive forces is in favor of tumor-induced suppression. Modified from: (Finn, 2008).
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6.3 Cancer immunotherapy
Activating the immune system for therapeutic benefit in oncology is known as an
“immunotherapy”. The cancer immunotherapy history is actually surprisingly long. William Coley,
a young surgeon at New York Memorial Hospital, noticed that some patients with sarcoma got
better and tumors shrank or even disappeared, when patients got Streptococcus pyogenes  infection
(erysipelas) (Hoption Cann et al., 2003).  Coley suspected that somehow the infection was
responsible for this miraculous cure and infected his patients with two inactivated bacterial strains
S. pyogenes and Serratia marcescens known as “Coley’s toxins” (Coley, 1891; Coley, 1894). His
first case was a success, a man with an inoperable sarcoma had complete response and the patient
was followed up until his death from a heart attack 26 years later (Nauts et al., 1953).
The passive transfer of anticancer monoclonal antibodies and donor T-cells in the context of
allogenic bone marrow transplantation are effective treatments for a variety of hematological and
solid malignancies (Dougan and Dranoff, 2009) and these immune treatments have been well-
established in oncology for several decades (Mellman et al., 2011). Antitumor immunity suggests at
least three sites for therapeutic intervention: promoting the tumor antigen presentation functions of
dendritic cells, promoting the production of protective T-cell responses in lymph nodes, and
overcoming immunosuppression in the tumor bed (Mellman et al., 2011).
The most important development for cancer immunotherapy recently is ipilimumab, a monoclonal
antibody to CTLA4, for late stage metastatic melanoma, either as first line therapy or after relapse
(Mellman et al., 2011). In brief, CTLA4 is a negative regulator of T-cells and it binds to members
of the B7 family of accessory molecules expressed by dendritic cells and other antigen-presenting
cells, thus inhibiting T-cell activation (see also section 6.1.2) (Chambers et al., 2001). Ipilimumab
blocks CTLA4 ligation to B7 recruiting T-cells and also blocks regulatory T-cells (Wing et al.,
2008).
A phase II trial with ipilimumab showed twofold survival benefit at 12 – 15?months, which was
durable after 2.5 years and included a complete response in some patients (Hodi et al., 2010). The
frequency of grade 3 or 4 immune-related adverse events was 10 – 15 % and 14 deaths related to
the study drugs occurred (2.1 %) (Hodi et al., 2010). In a second randomized trial involving 502
patients with previously untreated metastatic melanoma, the addition of ipilimumab to standard
dacarbazine therapy was shown to improve overall survival compared with dacarbazine alone (11.2
months versus 9.1 months) (Robert et al., 2011). Grade 3 or 4 adverse events occurred in 56.3 % of
patients  (27.5  % with  dacarbazine  alone),  but  no  treatment  related  deaths  occurred  (Robert  et  al.,
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2011). The data above indicates that long-lasting and durable cancer immunotherapy is possible, but
the treatment also involves high risks that have to be carefully considered.
6.4 Cancer immunovirotherapy
Oncolytic viruses including adenoviruses may break the immunotolerance of tumors and
outbalance tumor immunosuppression mechanisms leading to a significant anti-tumor effect
(Alemany and Cascallo, 2009). This concept is called “immunovirotherapy”. The concept relies on
oncolysis releasing tumor-specific antigens that are taken up by infiltrating antigen-presenting cells
for cross-presentation to cytotoxic T-cells for priming of (tumor) antigen-specific immune
responses (Diaz et al., 2007; Toda et al., 1999; Todo et al., 1999). The oncolytic process resulting
from viral replication is probably not effective enough for tumor eradication, but the triggering of
the immune response against the tumor could be long-lasting and more powerful, thereby overriding
the natural limitations of viruses. Therefore, oncolytic viruses show the ability to serve as both
cytotoxic and immunotherapeutic agents.
One approach in immunovirotherapy is to arm oncolytic viruses with such immunostimulatory
molecules that might trigger the desired anti-tumor immune response. Various candidates exist, for
example, tumor necrosis factor related apoptosis inducing ligand (TRAIL) (Bernt et al., 2005), IL-
12 (Lee et al., 2006), B7-1 (Lee et al., 2006), IL-4 (Post et al., 2007) or GM-CSF (Cerullo et al.,
2010). GM-CSF is among the most potent inducers of immunity (Dranoff, 2002) and it activates
NK-cells and antigen presenting cells (Andrews et al., 2005; Degli-Esposti and Smyth, 2005).
Promising preclinical and clinical results provided data supporting the concept and patients treated
with Ad5-d24-GMCSF displayed both anti-tumor and anti-adenovirus CD8+ T-cells immune
response without any severe adverse events (Cerullo et al., 2010).
Besides the rapid clearance of adenoviruses as a result of innate immunity, adaptive immunity also
creates long-lasting antibodies and memory against adenoviruses. This immunological obstacle
could limit the efficacy of adenoviral cancer gene therapy and it originates from the natural
frequency of adenovirus infections. Most adults retain Ad-specific cellular memory after childhood
exposure and more than 97 % of humans have pre-existing antibodies against group C
adenoviruses, but seroprevalence varies for other serotypes (Nayak and Herzog, 2010). These
antibodies do not eliminate the virus, but prevent adenovirus binding to cancer cells and promote
the phagocytosis of macrophages (Schagen et al., 2004; Yang et al., 1996). One option to
circumvent this is to use serotypes with lower natural prevalence.
The immune system can also be manipulated by adjuvant treatments to favor viral replication.
Cyclophosphamide is an alkylating agent that can inhibit innate immunity and down-regulate
56
regulatory T-cells, enhancing the antitumor effect of virotherapy (Di Paolo et al., 2006; Fulci et al.,
2006; Ghiringhelli et al., 2004; Ghiringhelli et al., 2007).
Another example of adjuvant therapy is verapamil. Verapamil is a calcium channel blocker
commonly used to treat cardiovascular diseases due to its effect of decreasing blood pressure.
Verapamil’s mechanism of action is understood because of the observation that several viruses
induce cell death and progeny release by disrupting intracellular calcium homeostasis (Carrasco,
1995; Ruiz et al., 2000). Gros et al showed in pre-clinical models that verapamil enhanced the
release of adenovirus from a variety of cell types, resulting in an improved cell-to-cell spread and
cytotoxicity and furthermore, the combination an oncolytic adenovirus (ICOVIR-5) with verapamil
improved the antitumor activity of ICOVIR-5 in mice (Gros et al., 2010).
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7. Overview to other selected oncolytic viruses and their clinical
use
Other viruses used in cancer gene therapy trials are the vaccinia virus, herpes simplex virus,
reovirus, Newcastle disease virus, and measles virus. More detailed description of the mumps virus
is also given because of interesting clinical results, even though it is not currently widely used.
7.1 DNA-viruses
7.1.1 Vaccinia virus
The Vaccinia virus belongs to the Poxviridae family and is highly immunogenic, as proven by the
production of small pox vaccines and eradication of small pox (Huovinen et al., 2007).  The
Vaccinia virus features many properties that make it attractive as a cancer therapy. The Vaccinia
virus has a high efficiency of infection, its 200?kbp genome allows the insertion of a large amount of
recombinant DNA without loss of infectivity, immunostimulatory properties can be used against
cancer and the production of conditionally replicative viruses is possible (Eager and Nemunaitis,
2011). Wild-type vaccinia virus does not selectively infect cancer cells, but tumor tropism can be
obtained by viral TK-gene deletion. The Vaccinia virus replication is possible in cancer cells
without the TK-gene because cancer cells possess relatively high concentrations of intracellular
nucleotide pools (Eager and Nemunaitis, 2011). The TK-gene can also be replaced with GM-CSF to
improve the anti-tumoral immune response (Mastrangelo et al., 1999).
TG4010 is a targeted immunotherapy agent based on a modified vaccinia virus Ankara coding for
MUC1 tumor-associated antigen and IL-2. IL-2 is able to reverse the suppression of the T-cell
response caused by the cancer-associated mucin MUC1 (Agrawal et al., 1998). In a phase IIB
controlled randomized trial, TG4010 was studied in advanced non-small-cell lung cancer combined
with cisplatin and gemcitabine (Quoix et al., 2011). When the combination treatment (74 patients)
group was compared to the chemotherapeutics only group (74 patients), six month progression free
survivals increased from 35.1 % to 43.2 %. The median overall survival was 10.7 months for the
combination group and 10.3 months for the chemotherapy only group (p=0.594).
In another phase II trial TG4010 was tested in the context of clear-cell renal carcinoma combined
with IFN-2 and IL-2 cytokines (Oudard et al., 2011). No objective clinical responses occurred, but
the median overall survival was 19.3 months (95% CI 11.1–30.2) for all patients (tot. 37 patients)
and 22.4 months (95% CI 12.7–32.1) for combination therapy recipients.
TG4010 has also been used for prostate cancer, where it decelerated the PSA doubling time
(Dreicer et al., 2009). In a phase II study 13 of 40 patients had more than two fold improvement in
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PSA doubling time and 10 patients had their PSA stabilized for over eight months. Overall, the
most frequent TG4010-related adverse events have been minor-to-moderate injection site reactions,
fatigue and flu-like symptoms in all studies.
7.1.2 Herpes simplex virus
Herpes simplex virus (HSV) is a double-stranded DNA virus that belongs to the Herpesvirus
family. According to current understanding eight different herpes virus species exist in humans
(Huovinen et al., 2007). There are two types of HSV, type I and type II, with rather similar biology
and replication. Clinical manifestation of HSV infection includes gingivostomatitis, vulvovaginitis,
other genital infections, neonatal infections, conjunctivitis, and encephalitis (Huovinen et al., 2007).
HSV type I is used in viral cancer therapy (Varghese and Rabkin, 2002).
Deletions in the viral genome also make HSV specific for cancer cell replication. One
modification involved inactivation of viral gene ICP6, which encodes the large subunit of
ribonucleotide reductase, an enzyme required for viral DNA replication (Goldstein and Weller,
1988). The second gene modification approach consists of deleting another viral gene, the ?-34.5
gene, which functions as the virulence factor during HSV infection (Chou et al., 1990). A third
approach includes TK-gene deletion (Martuza et al., 1991). HSV-1 can be used also in suicide gene
therapy, initially focused on using the HSV-TK gene to convert ganciclovir into toxic metabolites
(Springer and Niculescu-Duvaz, 2000) and arm the virus with immunostimulatory molecules such
as IL-2, IL-12 or soluble B7-1 (Carew et al., 2001; Toda et al., 1998; Toda et al., 1999). HSV-1 is
attractive for cancer therapy, because of the following characteristics (Varghese and Rabkin, 2002):
? it infects many cell types and it is cytolytic by nature
? well-characterized large genome (152 kbp) contains many nonessential genes that can be
replaced (up to 30 kbp) with multiple therapeutic transgenes
? a number of nonessential genes are associated with neurovirulence
? antiherpetic drugs are available
? the virus remains as an episome within the infected cell, even during latency, excluding the
possibility of insertional mutagenesis
The first replication competent oncolytic herpes virus was described in 1991 for the treatment of
malignant gliomas and featured a TK mutation (Martuza et al., 1991). Since then, several oncolytic
HSV-1 vectors have been studied in clinical trials, for example G207, 1716, NV1020, and
OncoVEXGM-CSF. G207 includes ?-34.5 gene deletion and lacZ insertion thereby disabling the UL39
gene, and it has been tested for recurrent glioma (Markert et al., 2000).  The 1716, deficient in
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ICP34.5 protein due to RL1 gene deletion, has been studied for recurrent glioma and melanoma
(MacKie et al., 2001; Rampling et al., 2000). The virulence of NV1020 is substantially weakened
by deletions of internal repeat sequences and insertion of an exogenous gene. The NV1020 has been
studied for colorectal cancer (Geevarghese et al., 2010; Kemeny et al., 2006) and its safety has been
good without any severe adverse events in  phase I trials and also some promising therapeutic
effects were observed.
OncoVEXGM-CSF (BioVax, Worcester, MA) is a modified replication-competent HSV-1 with
several novel genetic enhancements (e.g. human GM-CSF, intact TK) that make it a potent
oncolytic and immunogenic vector (Eager and Nemunaitis, 2011). In a phase I study for various
solid cancers, the most commonly detected side effects were local inflammation, erythema and
fever (Hu et al., 2006). From an efficacy point of view, three out of 26 patients had stable disease,
six patients had tumors flattened (injected and/or uninjected lesions) and four patients showed
inflammation of uninjected as well as the injected tumor.
Another phase II study of OncoVEXGM-CSF in metastatic melanoma demonstrated a 26 % objective
response by RECIST including uninjected regional and distant metastatic sites (Senzer et al., 2009).
Eight complete responses were seen out of 50 treated patients and overall survival was 58 % at 1
year and 52 % at 2 year.  Treatment related adverse effects (85 % of patients,  all  grade ? 2) were
limited primarily to transient flu-like symptoms (fever 52 %, chills 48 %, nausea 30 %, fatigue 32
%, vomiting 20 %, and headache 20 %).
7.2 RNA-viruses
7.2.1 Reovirus
Reovirus is highly prevalent in the human population, but not associated with any known human
disease and is thus considered to be harmless (Russell, 2002). Activated signaling pathways
downstream of KRAS or EGFR suppress the activity of double stranded RNA activated protein
kinase (PKR), which normally inactivates reovirus replication (Coffey et al., 1998; Strong et al.,
1998). Therefore, reovirus is tested in KRAS mutant tumors.
Systemic administration of reovirus has been tested in humans in two phase I monotherapy trials
(Gollamudi et al., 2010; Vidal et al., 2008). Commonly observed mild toxicities included fever,
fatigue, and headache.
In further clinical trials reovirus has been combined with chemotherapies like gemcitabine
(Lolkema  et  al.,  2011).  In  this  study,  dose  limiting  toxicity  was  detected  in  three  out  16  patients
consisting of two asymptomatic grade 3 liver enzyme elevation and one asymptomatic grade 3
troponin I elevation. In another phase I trial, Reolysin (wild-type oncolytic reovirus made by
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Oncolytics Biotech) was combined with docetaxel (Comins et al., 2010). Dose-limiting toxicity of
grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached.
Originally 25 patients were enrolled, but eventually 16 were suitable for response evaluation and
among those patients, one complete response and three partial responses were detected (Comins et
al., 2010).
7.2.2 Newcastle disease virus
Newcastle  disease  was  the  name  given  to  a  severe  avian  disease  that  occurred  in  England
(Alexander, 1988). This disease has plagued the poultry industry since it was first recognized in
1926 (Lam et al., 2011). Newcastle disease virus (NDV) causes a deadly infection in over 250
species of birds, both domestic and wild, resulting in substantial losses to the poultry industry
worldwide (Lam et al., 2011). NDV belongs to the family Paramyxoviridae and genus Avulavirus
(Mayo, 2002).
NDV is interesting from a cancer therapy point of view due to its properties, including being able
to replicate itself more rapidly in human tumor cells than in normal cells and cause of oncolytic
effects (Lam et al., 2011). NDV can replicate up to 10,000 times better in human transformed cells
than in most normal human cells (Pecora et al., 2002; Schirrmacher et al., 1999) and the majority of
tumor  cell  lines  can  be  infected  with  NDV (Fiola  et  al.,  2006).  It  has  been  suggested  that  NDV's
tumor cell activity is based on cancer-specific defects in the interferon pathway, but formal proof is
lacking for this hypothesis (Phuangsab et al., 2001). According to Lam et al there are many
advantages of using NDV in cancer treatment (Lam et al., 2011):
? The virus is not pathogenic to humans
? Ability to bind to the tumor cell surface via its hemagglutinin-neuraminidase glycoprotein
? Replication in tumor cells leads to an enhanced expression of viral antigen on tumor cell
surfaces
? Ability  of  virus  to  induce  synthesis  of  various  cytokines  (IFN  and  TNF),  as  well  as
stimulate production of heat shock proteins, adrenocorticotropic hormone, and tissue
inhibitor of metalloproteases
? Ability to stimulate TH-cells, CTLs, NK-cells, and macrophages
? Oncolytic activity and rapid growth in cancer cells
The NDV strains that have been most widely evaluated for the treatment of human neoplasms are
the nonlytic strain Ulster and the lytic strains MTH68/H, PV-701 and 73-T. PV-701 have shown
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good safety and the most commonly detected side effects have been flu-like symptoms, tumor site
specific reactions, infusion reactions, pain, leucopenia, thrombocytopenia and diffuse vascular
leakages (Laurie et al., 2006; Lorence et al., 2007; Pecora et al., 2002). The same studies have also
shown promising anti-cancer potency and no dose limiting toxicity was seen. Laurie et al reported
four stable disease responses among 16 treated patients with a response duration of six months
(Laurie et al., 2006), Lorence et al reported four major and two minor responses among 19 patients
and six patients survived for at least two years (Lorence et al., 2007).
7.2.3 Measles virus
Measles virus (MV) belongs to the family Paramyxoviridae, genus Morbillivirus (Huovinen et al.,
2007). Typical clinical manifestation includes high fever, cough, conjunctivitis and exanthema
among young children followed by lifelong immunity. In Western countries, natural MV infections
are mostly eradicated by vaccinations but in developing countries more than one million children
die annually due to Measles infections (Huovinen et al., 2007). The MV vaccine strain was isolated
in 1954 from the throat washings of an 11-year-old measles patient named David Edmonston and
was attenuated by serial tissue culture passages (Msaouel et al., 2009).
The virus infects efficiently on Epstein-Barr virus-transformed B-cell lines, which might explain a
dramatic response in an eight-year-old child whose large, untreated retro-orbital endemic Burkitt's
lymphoma regressed completely during concomitant measles virus infection (Bluming and Ziegler,
1971). Nevertheless, wild-type MV does not propagate in most cancer cell lines, but certain
members of the Edmonston vaccine lineage are potently and selectively oncolytic (Grote et al.,
2001; Peng et al., 2001; Peng et al., 2002). The tumor tropism of attenuated MV-Edmonston results
from the mutations in the viral attached haemagglutinin protein that enhance its ability to interact
with CD46, a regulator of complement activation that is expressed at high levels on the surface of
most human tumors (Erlenhofer et al., 2002).
In a phase I trial with intraperitoneal administration of an oncolytic measles virus (MV-CEA
virus, which express CEA to permit real time monitoring) for recurrent ovarian cancer, 14 out of 21
patients showed disease stabilization and five patients had significant decreases in CA-125 levels
(Galanis et al., 2010). In this study there was no dose-limiting toxicity and basically all side effects
were grade 2 or less.  There was only one grade 3 toxicity (arthralgia) observed in one patient after
a fourth round of virus administration. The most common side effects included fatigue (~34 %),
fever (~38 %), anorexia (~29 %), abdominal pain (~24 %), and nausea (~19 %) (Galanis et al.,
2010).
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Another MV strain, Edmonston-Zagreb vaccine, was studied in five patients with cutaneous T-cell
lymphomas (Heinzerling et al., 2005). In this phase I trial, partial regression was observed in four of
the intratumorally treated lesions, while one of the treated lesions demonstrated no response. From
an immunological perspective, an increase of the IFN-?/CD4 and IFN-?/CD8 mRNA ratios,  and a
reduced CD4/CD8 ratio were observed (Heinzerling et al., 2005). Safety was good also in this
study.
A third  MV virus  used  in  clinical  trials  is  MV-NIS,  which  express  the  NIS gene  to  concentrate
radioisotopes inside cells (Dingli et al., 2003; Dingli et al., 2004). There are at least two open
clinical  trials  ongoing:  a  trial  of  intratumoral  and  resection  cavity  administration  of  MV-CEA  in
patients with recurrent glioblastoma multiforme (NCT00390299) and a second trial of intravenous
administration of MV-NIS with or without cyclophosphamide in patients with multiple myeloma
(NCT00450814).
7.2.4 Mumps virus
The Mumps virus is a member of the genus Paramyxovirus in the family Paramyxoviridae and the
typical clinical manifestation of virus infection is parotitis among juveniles (Huovinen et al., 2007).
The most promising clinical study performed with Mumps virus was conducted in Japan using a
tissue culture adapted strain of mumps virus (Asada, 1974). Ninety patients with various terminal
malignancies were treated with minimal toxicity (occasional fever) but the clinical responses were
most encouraging. In 37 of 90 patients, the tumor disappeared or decreased to less than half of its
original size. Minor regressions were observed in an additional 42 patients (Russell, 2002). For an
unknown reason these excellent results did not lead to the further more widespread study of mumps
virus as an oncolytic agent (Russell, 2002).
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8. Clinical adenoviral gene therapy trials
The first modern oncolytic virus in clinical trial was ONYX-015, E1B deleted oncolytic
adenovirus, that was used for recurrent head and neck cancer patients in 1996 with a good safety
profile (Ganly et al., 2000). The initial trials tested the efficacy of the ONYX-015 as a single agent
and approximately 15-20 % response rate (= stable disease or better) was observed (Ganly et al.,
2000; Nemunaitis et al., 2000). No responses were seen for other cancer types such as ovarian,
pancreatic and colorectal cancer (Hamid et al., 2003; Hecht et al., 2003; Vasey et al., 2002). Due to
the limited activity as a single agent, ONYX-015 has also been studied with chemotherapy and
radiotherapy. The response rate was improved from ~20 % to 65 % when ONYX-015 was
combined with cisplatin and 5-fluorourasil compared to chemotherapy only (Khuri et al., 2000).
The complete response rate in nasopharyngeal cancer patients treated with radiotherapy plus rAd-
p53 was 2.73 times higher than the group receiving radiotherapy alone (66.7 % vs. 24.4 %). A six-
year follow-up data in the same study showed that combination therapy significantly increased the
5-year locoregional tumor control rate by 25.3 %, but significant results were not observed in 5-year
overall survival (Pan et al., 2009). In another phase II trial of head and neck cancer, radiotherapy
(70 Gy) plus rAd-p53 improved tumor reduction rate from 62 % to 90 % (Zhang et al., 2003b).
Zhang et al also reported 2.31 times higher complete response rate two months after treatment with
rAd5-p53 combined with radiotherapy (Zhang et al., 2005).
Patients with malignant glioma have been treated successfully with a AdvHSV-tk vector encoding
thymidine kinase gene and lacking the E1 and E3 regions. Seventeen patients received AdvHSV-tk
gene therapy by local injection into the wound bed after tumor resection, followed by intravenous
ganciclovir.  The  control  group  of  19  patients  received  standard  care  consisting  of  radical  tumor
excision followed by radiotherapy. The median survival time increased from 37.7 to 62.4 weeks
(Immonen et al., 2004). This vector is also known as Cerepro and is developed by Ark Therapeutics
(Kuopio, Finland). However, the Committee for Human Medicinal Products did not approve
Cerepro 2008, citing a negative risk-benefit profile due to insufficient efficacy and the risk of
hemiparesis and seizures (Sheridan, 2011).
During the last two decades, an increasing number of clinical trials have been conducted with
different  viruses  for  various  cancers  as  a  single  therapy  or  combined  with  other  regimes.
Approximately 140 clinical cancer gene therapy trials with adenoviruses have been conducted since
1996.
In a larger perspective, adenoviral trials have shown very good safety for various diseases and
only one treatment related death has been documented (Raper et al., 2003). In that study an 18 year
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old male with partial ornithine transcarbamylase (OTC) deficiency died after adenovirus serotype 5
(E1 and E4 deleted containing human OTC cDNA) administration through the hepatic artery (Raper
et al., 2003). His clinical course was marked by systemic inflammatory response syndrome
(elevated IL-6 and Il-10, but normal TNF-alpha after infusion), biochemically detectable
disseminated intravascular coagulation, and multiple organ system failure, leading to death 98 h
following gene transfer. This experience pointed out the limitations of animal studies in predicting
human responses, substantial subject-to-subject variation, and the need for detailed understanding
of the immune response towards adenovirus vectors. Shortly  after  this  event,  more  concern  about
gene therapy safety raised the observations of five patients with X-linked SCID who developed T-
cell leukemia after retrovirus treatment (Hacein-Bey-Abina et al., 2008). The retrovirus used in this
trial contained an enhancer sequence that activated proto-oncogenes leading to T-cell proliferation
and leukemia (Hacein-Bey-Abina et al., 2008; Sheridan, 2011). Generally in all reported clinical
trials, the most common side effects have been pain at the injection site, fatigue and development of
self-limited fever. No treatment related deaths have occurred in cancer trials to our knowledge.
A ten year follow-up data for 146 non-small-cell lung cancer (NSCLC) patients treated with
adenovirus gene therapy given as second line treatment in eight different trials during 1995 – 2005
has been also reported (Nemunaitis et al., 2007). A long-term follow-up of reported adverse events
showed no grade 3 or grade 4 adverse events. Mean survival was 334 days and the proportion of
patients alive at 1 year, 2 years and 5 years were 30 %, 12 %, and 6 %, respectively. When this data
was compared to current chemotherapeutic options in the second line for advanced NSCLC, there
was no difference in one year survival. One year survivals were 28 – 30 % for pemetrexed,
docetaxel and erlotinib (Nemunaitis et al., 2007). Based on this report by Nemunaitis et al there are
no obvious concerns towards the long-term effect of therapy involving adenoviral vectors in
NSCLC patients. Long-term follow-up data for other cancer types has not been reported to our
knowledge.
According to the National Institute of Health (NIH) database (April, 2012) there are currently 23
open and active clinical adenoviral cancer gene therapy trials (www.ClinalTrials.gov).  Table  7
summarizes the basic characteristics of these trials. Trials with unknown status are excluded.
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Table 7. Open adenoviral clinical gene therapy trials for cancer at April, 2012. Data adapted from:
www.ClinicalTrials.gov.
Type of cancer Number of trials Therapy approach (no.) and design
Bladder cancer 1 Therapeutic transgene: 1 (GM-SCF)
Replicative adenovirus: 1
Breast cancer 1 Therapeutic transgene: 1 (GM-CSF)
Vaccination/Immunization: 1
Glioblastoma 3 Therapeutic transgene: 1 (TK)
Replicative adenovirus: 2
Head and Neck cancer 1 Therapeutic transgene: 1 (Endostatin)
Hepatocellular cancer 1 Vaccination/Immunization: 1
Lung cancer 4 Therapeutic transgene: 4 (p53, CCL21)
Infected dendritic cells: 3
Melanoma 6 Therapeutic transgene: 4 (IFN-?, IFN-?, IL-12, CD40L)
Replicative adenovirus: 1
Infected dendritic cells: 1
Mesothelioma 1 Therapeutic transgene: 1 (IFN-?)
Prostate cancer 3 Therapeutic transgene: 3 (PSA, PNP)
Vaccination/Immunization: 2
Not specific 2 Therapeutic transgene:  2 (GM-CSF, PNP)
Replicative adenovirus:  1
rAd-p53 (or Gendicine) is a replication deficient adenovirus encoding the human tumor suppressor
protein p53. China's State Food and Drug Administration (SFDA) approved Gendicine for clinical
use in October 2003 and licensed its commercial production in spring of 2004 (Guo and Xin, 2006).
SFDA approved Gendicine as a treatment for head and neck cancer based on a small clinical trial,
where more patients had complete response with radiotherapy plus Gendicine (64 %) than with
radiotherapy alone (19 %) (Guo and Xin, 2006).
Oncolytic virus research took another major step forward in November 2005 when a second
cancer gene therapy product Oncorine was approved by SFDA (Garber, 2006). Shanghai Sunway
Biotech's genetically modified adenovirus H101 (Oncorine) was approved for head and neck cancer
in combination with chemotherapy. This approval was based on the randomized phase III trial
findings where cisplatin, 5-fluorourasil (=PF regiment) plus intratumoral injection of H101 or
adriamycin, 5-fluorourasil (=AF regiment) plus H101 increased overall response rates compared to
chemotherapy alone (Xia et al., 2004). Overall responses were 78.8 % (PF plus H101), 39.6 % (PF
alone), 50.0 % (AF plus H101) and 50.0 % (AF alone) (Xia et al., 2004). Survival data was not
reported and the approval in Europe and in United States will depend on survival benefit. Survival
data was not reported because Chinese regulators at that time based their review on the objective
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response rate, not survival. Besides, survival follow-up is difficult because many of Sunway's
patients live in isolated rural areas and are never seen by their doctors again. Shanghai Sunway
Biotech is also testing H101 in lung cancer and has bought the rights to ONYX-015 (Garber, 2006).
Western critics have questioned these results due to lack of available information (Guo and Xin,
2006; Sheridan, 2011).
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AIMS OF THE STUDY
The main aims of this thesis are to evaluate in preclinical models the interactions of replication-
deficient  adenoviruses  and  radiotherapy  (study  I),  and  the  safety,  efficacy  and  immunological
factors of oncolytic adenovirus treatments in patients with advanced solid cancers (studies II-IV).
The specific aims are:
1. To study the combination of replication-deficient adenoviruses and radiotherapy in vitro and
to analyze the mechanisms of radiation-mediated upregulation of adenoviral transgene
expression (I).
2. To study the safety and efficacy of Ad5/3-Cox2L-d24, a triple mutant oncolytic adenovirus
with the COX-2 promoter controlling E1A and the serotype 3 knob, in 18 cancer patients
(II).
3. To study the safety and efficacy of a novel oncolytic adenovirus ICOVIR-7 in 21 patients
with advanced metastatic cancer (III).
4. Our primary goal was to study the safety and anti-tumor effects of three doses of oncolytic
adenovirus versus single administration in 124 cancer patients. Secondly, we studied T-
cells´ responses against tumor and viral epitopes (IV).
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MATERIALS AND METHODS
1. Cell lines
Table 8. Human cell lines used in the studies.
Cell line Description Source Original study
LNM35/eGFP Lung carcinoma cell line,
express GFP
T. Takahashi, Honda Research
Institute Japan, Saitama, Japan
I
M4A4-LM3 Breast cancer cell line,
express GFP
Goodison S., Department of
Pathology, University of Florida,
FL, USA
I
PC-3MM2 Prostate cancer cell line Isaiah J. Fidler, M.D. Anderson
Cancer Center, Houston, TX, USA
I
293 Embryonic kidney cells
transformed with Ad5 E1
American type culture collection,
Manassas, VA, USA
I
A549 Human lung
adenocarcinoma
American type culture collection,
Manassas, VA, USA
II, III, IV
Breast cancer cell line M4A4-LM3 (Goodison et al., 2005) and lung cancer cell line
LNM35/eGFP (courtesy of T. Takahashi, Honda Research Institute, Japan) were cultured in RPMI
supplemented with 10 % fetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL penicillin and 100
?g/mL  streptomycin.  Both  cell  lines  express  green  fluorescent  protein  (GFP)  under  the  CMV
promoter. PC-3MM2 prostate cancer cells are a highly metastatic hormone refractory sub line of
PC-3  (courtesy  of  Isaiah  J.  Fidler,  MD Anderson  Cancer  Center,  Houston,  TX).   PC-3MM2 cells
were cultured in DMEM supplemented with 10 % FCS, 2 mM L-glutamine, 100 U/mL penicillin,
100 ?g/mL streptomycin and 1 mM sodium pyruvate (Sigma).
2. Viral constructs
2.1 Replication deficient adenoviruses
For large scale production, all replication deficient adenoviruses were propagated in 293 cells. The
large scale virus preps were purified by standard cesium chloride gradient centrifugation and VP/ml
concentrations were determined by absorbance at 260 nm of purified adenovirus. TCID50- assay
was used to determine the pfu/ml titer. The presence of correct genes, the absence of wild type
contamination and correct viral structure was confirmed by PCR and sequencing. More specific
construction conditions are described in original studies referred to in the text with roman numerals
(I-IV).
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Table 9. Replication deficient adenoviruses used in study I.
Virus Features References
Ad5-luc1 Ad5 serotype, deleted E1 region, SV40-luciferase expression cassette
in the E1-region under a CMV promoter
(Kanerva et al., 2002a)
(Krasnykh et al., 2001)
Ad5/3-luc1 Ad5 serotype, Ad3 knob for enhanced transduction, deleted E1 region,
luciferase as a transgene
(Kanerva et al., 2002a),
(Krasnykh et al., 1996)
Ad5-luc-RGD Ad5 serotype, deleted E1 region, RGD-4C motif in the HI-loop to
enhance binding to integrins, luciferase as a transgene
(Dmitriev et al., 1998)
Ad5-GL Ad5 serotype, deleted E1 region, luciferase and GFP as a transgenes (Wu et al., 2002)
Ad5-pk7-GL Ad5 serotype, deleted E1 region, seven polylysines at the COOH
terminus to enhance binding to HSPG, luciferase and GFP as a
transgenes
(Wu et al., 2002)
Ad5-mdr-luc Ad5 serotype, deleted E1 region, luciferase as a transgene controlled
by multi-drug resistance (mdr) promoter
(Bauerschmitz et al.,
2008)
Ad5-ala-luc Ad5 serotype, deleted E1 region, luciferase as a transgene controlled
by ?-lactalbumin (ala) promoter
(Bauerschmitz et al.,
2008)
Ad5-cox2-luc Ad5 serotype, deleted E1 region, luciferase as a transgene controlled
by cyclo-oxygenase (COX) promoter
(Bauerschmitz et al.,
2008)
Ad5-vegf-luc Ad5 serotype, deleted E1 region, luciferase as a transgene controlled
by vascular endothelial growth factor (VEGF) promoter
Courtesy of Koichi
Takayama
2.2 Oncolytic adenoviruses
All oncolytic adenoviruses used in this study were cloned as described on the previous page
except A549 were used for propagation. A more detailed description is found in the original
publications.
Table 10. Oncolytic adenoviruses used in studies II, III and IV.
Virus Features References
Ad5/3-cox2L-d24 Serotype 5, Ad3 knob, tumor specific cox2L- promoter, 24 bp
deletion at E1A region
(Pesonen et al., 2010)
ICOVIR-7 Serotype 5, RGD-motif to enhanced integrin binding, tumor
specific E2F-promoter and E2F hairpins for optimal replication,
DM insulator for enhanced specificity and Kozak sequence for
optimal E1A expression
(Nokisalmi et al., 2010),
(Rojas et al., 2009)
CGTG-102 a.k.a
Ad5/3-d24-GMCSF
Serotype 5, Ad3 knob, 24 bp deletion at E1A region, GM-CSF
transgene in E3 region
(Koski et al., 2010)
Ad5-RGD-d24-
GMCSF
Serotype 5, RGD-motif to enhanced integrin binding, 24 bp
deletion at E1A region, GM-CSF transgene in E3 region
(Pesonen et al., 2011)
Ad5-d24-GMCSF Serotype 5, 24 bp deletion at E1A region, GM-CSF transgene in
E3 region
(Cerullo et al., 2010)
Ad3-hTERT-E1 Serotype 3, tumor specific hTERT-promoter at E1 region (Hemminki et al., 2011)
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3. In vitro methods and protocols (I)
3.1 Cell irradiation
Irradiation was performed with a linear accelerator (Model: Clinac 600C/D, Manufacturer: Varian
Medical Systems, Palo Alto, CA, USA) using a 6 MV photon beam (nominal energy) and dose rate
400 MU/min (~ 4 Gy/min). In in vitro studies cells were irradiated on tissue culture plates (6- or 24
wells). The plates were arranged on custom made water phantom and irradiated through 1 cm thick
plastic  phantom bottom and 1  cm thick  layer  of  water  in  the  phantom (gantry  angle  180  degrees,
field size 40 cm x 40 cm). The source to phantom distance was 100 cm and the absorbed dose was
calculated at the depth of cells (2 cm from the bottom of the phantom).
Figure 8. Cancer cell irradiation settings. Tissue culture plates were arranged
on plastic water phantom on the treatment table. A maximum treatment field
size (40 cm x 40 cm) was used to provide homogenous radiation dose to all
tissue culture plates.
3.2 Fluorescence-activated cell sorting analysis
For cell surface receptor analysis, flow cytometric analysis was performed. PC-3MM3 and M4A4-
LM3 cells (2 x 105) were incubated for 20 min at 4°C with the following primary antibodies at
1:200 dilution: anti-CAR (clone RmcB; Upstate Cell Signaling Solutions/Millipore, Lake Placid,
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NY), anti-HSPG (clone F58-10E4; Seikagaku, Falmouth, MA), anti-?v?3 integrin (clone LM609;
Chemicon International/Millipore, Temecula, CA), anti-?v?5 integrin (clone P1F6; Chemicon
International/Millipore), or anti-CD46 (clone E4.3; BD Biosciences, San Jose, CA). Cells were
washed with fluorescence-activated cell-sorting (FACS) buffer (phosphate-buffered saline
containing 2 % FBS) and incubated with a 1:200 dilution of phycoerythrin (PE)-labeled secondary
antibody (goat anti-mouse polyclonal antibody; BD Biosciences) for 30 min at 4°C. Cells were
washed with FACS buffer and analyzed by flow cytometry (FACSCalibur; BD Biosciences) to
determine receptor expression levels. Non-stained cells were used as a negative control. The
method is adapted from (Hakkarainen et al., 2007).
3.3 Transgene analysis
Transgene activity was determined 24 h after infection (= 48 h after irradiation) if not stated
otherwise. For analysis a luciferase assay system (Promega, Madison, WI, TopCount Luminometer,
Perkin-Elmer) was used according to the manufacturer’s protocol. Flow cytometric analysis was
used to determine the proportion of GFP positive cells (gene transfer efficiency) and the intensity of
fluorescence in positive cells (level of gene expression).
3.4 Mass spectrometry analysis
HPLC analysis was carried out on an LC Packings system (Amsterdam, Netherlands). This
consisted of FAMOS carousel microautosampler connected to an outer pump (Pharmacia LKB,
Sweden), Ultimate micro-HPLC pump with UV detector, and Switchos, a 6x2 valve switching
device. A PepMap™ C18 column (300 ?m X 15 cm, 100Å, 3 ?m, LC Packings) was used with 0,05
% (v/v) trifluoroacetic acid (TFA) 5 % (v/v) acetonitrile (ACN) as solution A and 0.4 %
TFA/80ACN as solution B, at a flow rate of 4 ?l/min. The PepMap™ column was preceded by a ?-
precolumn cartridge (C18 PepMap, 5?m, 100 Å, 300 um i.d.×5 mm) in a holder (LC Packings). The
technical setup was controlled by the Ultichrom™ 3.1 software (LC Packings, Amsterdam,
Netherlands). The solvents were continuously sparged with helium. Peptide trypsin digests were
eluted from the column with a linear gradient of 5 % to 50 % solution B within 115 min. The wash
and loading solvent used with the Famos autosampler to the ?-precolumn was 0.1 % TFA at a flow
rate of 10?l/min from the outer pump.
The mass spectrometric analyses were performed on LC-interfaced Bruker Esquire 3000 plus ion
trap mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray source
set to the positive ion mode. The auto-MS/MS parameters were the following: scan range m/z 200–
2000, scan speed 13000 m/z ??1, nebulizer flow 7 psi, dry gas flow 6.0 L/min, dry temperature
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150ºC, capillary ?2 kV, skimmer 40V, ion charge control (ICC) target 11000, maximum
accumulation time 200 ms, spectra averages 10, and rolling averages 5.
Protein identifications were performed by NCBInr and Swissprot Database searching, through
Mascot, and MS/MS datasets were performed via BioTools™ 3.1 software (Bruker Daltonic,
Matrix  Science  Ltd,  UK).  MS  and  MS/MS  tolerance  of  respectively  0.5  Da  and  1  Da  and  one
missing cleavage site were allowed. Carbamidomethyl-cysteine and oxidation of methionine
residues were considered in the fixed and variable modifications respectively. The resultant data
was further evaluated by comparing the scores, the calculated and observed molecular mass and pI
values, as well as the number of peptides matching to the protein and mostly, the percent sequence
coverage.
3.5 Molecular inhibitors
DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 and heat shock protein 90 (HSP90)
inhibitor 17-AAG were purchased from TOCRIS Bioscience (Bristol, UK), and topoisomerase-I
inhibitor (Topo-Ii) irinotecan from Mayne/Hospira UK Limited (Warwickshire, UK). DNA-PK
potentiates the effect of radiation and some chemotherapeutics like doxorubicin and etoposide
(Zhao et al., 2006). The 17-AAG inhibits HSP90 chaperon activity, oncogenic proteins such as
p185erbB-2, and has anti-tumor properties (Hostein et al., 2001; Schnur et al., 1995). Irinotecan
prevents DNA replication and transcription by inhibiting topoisomerase-I enzyme.
3.6 Quantitative real-time polymerase chain reaction
Total DNA was extracted from M4A4-LM3 cells using the QIAamp DNA mini kit (Qiagen). PCR
amplification was based on primers and probe targeting the E4 gene (Kanerva et al., 2002b). Human
?-actin  primers  and  probe  were  used  as  an  internal  control  and  to  normalize  the  number  of  viral
DNA copies for the amount of genomic DNA (Alvarez-Lafuente et  al.,  2007).  The real-time PCR
conditions for each 20-?l reaction were as follows: 2 x LightCycler480 Probes Master Mix (Roche),
500 nM each forward and reverse primer, 150 nM each probe, and 5 µl extracted DNA. PCRs were
carried out in a LightCycler (Roche) under the following cycling conditions: 10 min at 95°C, 50
cycles of 15 s at 95°C, and 1 min at 60°C, and 10 min at 40°C. All samples were tested in triplicate.
A regression standard curve was established using DNA extracted from serial dilutions of pAd5easy
plasmid (from 109 to 101 copies).  Known amounts  of  human genomic  DNA (800,  80,  8,  0.8,  and
0.08 ng) were used to generate a standard curve for the ?-actin gene.
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3.7 Immunofluorescence staining and confocal microscopy
Phospho-?H2AX foci analysis was used to quantify double strand breaks (DSBs) induced by
adenovirus, irradiation, and specific inhibitors: DNA-PK inhibitor (DNA-Pki) (NU-7441, 1 mM),
HSP90 inhibitor (HSP90i) (17-AAG, 500 nM), or topoisomerase-I inhibitor (Topo-Ii) (irinotecan,
200 mM). The cells were plated on LabTek chambers and infected with Ad5-luc1. Finally, the cells
were washed and fixed with 4 % paraformaldehyde for 10 min at room temperature and stored at 4
°C in phosphate-buffered saline. For DNA DSB quantification, the cells were immunostained with
rabbit polyclonal anti-?H2AX and Alexa488 conjugated secondary antibody (Molecular
Probes/Invitrogen). The cells were mounted with Vectashield with counterstain for nuclei with 4´,6
diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA). Cells were visualized
using Zeiss LSM 5 Duo laser scanning confocal microscope (Jena, Germany). Analysis of ?H2AX
foci number and size were done with ImageJ software. In a single experiment, at least 40 cells from
five independent fields were analyzed.
74
4. Treatment of patients with oncolytic adenoviruses (II, III, IV)
4.1 Advanced therapy access program (ATAP)
The Advanced Therapy Access Program was started in 2007 in partnership with the International
Comprehensive Cancer Center Docrates, Helsinki, Finland. The purpose of this program is to offer
experimental therapies to patients with metastatic cancers refractory to conventional therapies.
ATAP is a personalized therapy program, not a randomized clinical trial. Altogether about 300
patients have undergone the oncolytic adenovirus therapy through this program so far. All
treatments  in  this  study  were  given  in  the  context  of  a registered (ISRCTN 10141600) ATAP.
ATAP is regulated by FIMEA (Finnish Medicines Agency) as determined by EC/1394/2007.
Treatments were performed according to Good Clinical Practice and the Helsinki Declaration of
World  Medical  Association  (Article  35).  FIMEA  requires  the  reporting  of  treatment  results  and
adverse events. Required reports to FIMEA have been provided as requested.
4.2 Patient selection and follow-up
Altogether 157 cancer patients were treated in three patient series (II-IV). All patients voluntarily
contacted  the  clinic  and  the  suitability  of  each  patient  for  viral  therapy  was  evaluated  before
treatment based on their medical history, clinical evaluation and other diseases.  Detailed written
information about the treatment was given to the patient by the oncologist and the patient signed the
form of consent. Possible adverse events caused by the treatment were also explained and written
information regarding this issue was provided to the patients and their caregivers.
Symptoms were assessed by interviewing the patient at each visit and by collecting information
from  medical  records.  Patients  were  monitored  overnight  at  the  hospital  and  thereafter  as
outpatients for a minimum 28 days post treatment. All adverse events (AE) were graded from 1 to 4
according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Pre-existing
symptoms were not listed as adverse effects if they did not become worse. However, if a symptom
became more severe, for example, pretreatment grade 1 changed to grade 2 after treatment, it was
scored  as  grade  2.  The  term  “serious  adverse  event  (SAE)”  was  used,  if  the  adverse  event  was
possibly or probably treatment related and it resulted in patient hospitalization, prolongation of
hospitalization, life threatening situation or death.
The inclusion criteria were: solid tumors refractory to conventional therapies, progressive disease,
WHO performance score ? 3 and no major organ function deficiencies. Exclusion criteria were:
organ transplant, HIV or other major immunosuppression, brain metastasis, elevated bilirubin, ALT
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or AST elevated more than three times above upper limit of normal, severe thrombocytopenia and
other severe disease or organ malfunction.
4.3 Analysis of treatment efficacy
Tumor assessment by computer tomography (CT) or magnetic resonance imaging (MRI) was
performed before treatment and again about six weeks later. Response Evaluation Criteria in Solid
Tumors (RECIST) (Therasse et al., 2005; Therasse et al., 2006) was applied to overall disease status
including injected and non-injected tumors. RECIST categories are:
? Complete Response (CR): Disappearance of all target lesions
? Partial  Response  (PR):  At  least  a  30  %  decrease  in  the  sum  of  the  longest  diameter  of
target lesions, taking as reference the baseline sum of longest diameter
? Stable Disease (SD): Neither sufficient for PR nor PD
? Progressive Disease (PD): At least a 20 % increase in the sum of the longest diameter of
target lesions, or at least one new lesion
In addition to the standard criteria above, we used Minor Response (MR, 10-30 % reduction in the
size of lesions) as an indicator of cases where biological activity might be present. Tumor density
was evaluated according to the “Choi criteria” (Choi et al., 2007), which have been proposed useful
in the context of oncolytic viruses (Park et al., 2008). Choi analysis is based on tumor size and
density (Hounsfield unit) on CT and maximum standardized uptake value (SUVmax) on
[18F]fluorodeoxyglucose positron emission tomography (FDG-PET). Choi et al proposed criteria
where a decrease in tumor size of more than 10% or a decrease in tumor density of more than 15%
on CT had a sensitivity of 97% and a specificity of 100% (Choi et al., 2007).
4.4 Quantitative real-time polymerase chain reaction for patients
Total DNA was extracted from serum by adding 3 µg of carrier DNA (polydeoxyadenylic acid;
Roche, Mannheim, Germany) to 400 µl of serum and using the QIAamp DNA mini kit (Qiagen
GmbH,  Hilden,  Germany).  Extracted  DNA  was  eluted  in  60  µl  nuclease-free  water  and  DNA
concentration was measured by spectrophotometry. PCR amplification was based on primers and
probe targeting the E1A region flanking the 24 bp deletion (forward primer 5´-
TCCGGTTTCTATGCCAAACCT-3´, reverse primer 5´-TCCTCCGGTGATAATGACAAGA-3´
and probe onco 5´FAM-TGATCGATCCACCCAGTGA-3´MGBNFQ). In addition, a probe
complementary to a sequence included in the 24 bp region targeted for deletion was used to test the
76
samples for the presence of wild-type adenovirus infection (probe wt 5´VIC-
TACCTGCCACGAGGCT-3´ MGBNFQ).
The real-time PCR conditions for each 25 µl reaction were as follows: 2X LightCycler480 Probes
Master Mix (Roche, Mannheim, Germany), 800 nM each forward and reverse primer, 200 nM each
probe, and 250 ng extracted DNA. PCR reactions were carried out in a LightCycler (Roche) under
the following cycling conditions: 10 min at 95 °C, 50 cycles of 10 s at 95 °C, 30 s at 62 °C, and 20 s
at 72 °C and 10 min at 40 °C. All samples were tested in duplicate. TaqMan exogenous internal
positive  control  reagents  (Applied  Biosystems,  Carlsbad,  CA,  USA)  were  used  in  the  same  PCR
runs to test each sample for the presence of PCR inhibitors. A regression standard curve was
generated using DNA extracted from serial dilutions of the tested virus (1 x 108-10 VP/ml) in normal
human serum.  The  limit  of  detection  and  limit  of  quantification  for  the  assay  were  500  VP/ml  of
serum. All positive samples were further confirmed by real-time PCR using LightCycler480 SYBR
Green I Master mix (Roche). Primers specific for each virus used in this study are listed below:
Table 11. List of primers.
Tested virus Forward primer Reverse primer References
Ad5/3-cox2L-d24 5´-CACGTCCAGGAACTCCTCAG-3´ 5´-CGGCCATTTCTTCGGTAATA-3´ (Pesonen et al., 2010)
ICOVIR-7 ??-GCGGGAAAACTGAATAAGAGG-3? 5?-CGGAGCGGTTGTGAACTG-3? (Nokisalmi et al., 2010)
CGTG-102 a.k.a
Ad5/3-d24-GMCSF
??-GGAGTGCGCCGAGACAAC-3? ??-ACTACGTCCGGCGTTCCAT-3? (Koski et al., 2010)
Ad5-RGD-d24-GMCSF Ad5-a forward:
??- ACAAACGCTGTTGGATTTATGC-3?
Ad5-b forward:
 5?-AAACACCACCCTCCTTACCTG-3?
RGD reverse:
 5?-GATGGGCAGAAACAGTCTCC-3?;
GMCSF reverse:
 5?-TCATTCATCTCAGCAGCAGTG -3?)
(Pesonen et al., 2011)
Ad5-d24-GMCSF ??-AAACACCACCCTCCTTACCTG-3? ??-TCATTCATCTCAGCAGCAGTG-3? (Cerullo et al., 2010)
Ad3-hTERT-E1 ??-
CATGATATCGTGCCAGCGAGAAGA
GTTTT-3?
??-
CATTCTAGAGCGAGCACAATAGTTC
TTTCA-3?
(Hemminki et al., 2011)
4.5 Cytokine analysis
Cytokine analysis was done with BD Cytometric Bead Array Human Soluble Protein Flex Set
(Becton Dickinson) according to the instructions of the manufacturer. FCAP Array v1.0.1 software
was used for data analysis. Patient’s serum samples were used in 1:4 dilution.
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4.6 Elispot analysis
Peripheral blood mononuclear cells (PBMC) were used to evaluate the induction of tumor and
adenovirus specific immunity following treatment as reported (Cerullo et al., 2010; Koski et al.,
2010). PBMCs were isolated by Percoll gradient. Cells were frozen in CTL-CryoABCTM serum-
free  media  (Cellular  Technology  Ltd.  Cleveland,  Ohio).  ELISPOT  was  performed  according  to
MABtech manufacturer instructions (h-IFN-gamma ELISPOT PRO 10 plate kit). For adenovirus
ELISPOT, cells were stimulated with the HAdV-5 Penton peptide pool (ProImmune, Oxford, UK).
For  the  anti-tumor  response  survivin  (BIRC5  PONAB),  pool  of  CEA+Ny-ESO-1,  pool  of  c-Myc
+SSX2, MAGE-3 and WT-1 peptides were used (ProImmune). No pre-stimulation of PBMCs was
done in order to avoid artificial or incorrect signals and to ensure adequate viability of cells which
might be compromised during prolonged culture.
4.7 Neutralizing antibody titer determination
293 cells were seeded at a density of 1 × 104 cells/well on 96-well plates and cultured overnight.
Serum samples were incubated at 56°C for 90 minutes to inactivate complement, and a 4-fold
dilution series (1:1 to 1:16,384) was prepared in serum-free DMEM (Sarkioja et al., 2008).
Ad5lucRGD (Kanerva et al., 2002b) was used for ICOVIR-7 and Ad5/3-luc1 (Kanerva et al.,
2002b) for Ad5/3-cox2L-d24. Control viruses were mixed with serum dilutions and incubated at
room temperature for 30 minutes. Cells in triplicates were infected with 100 VP/cell, and growth
medium with 10 % FCS was added 1 hour later. Twenty-four hours post infection, cells were lysed
and luciferase activity was measured (Luciferase Assay System, Promega; TopCount Luminometer,
Perkin-Elmer). Luciferase readings were plotted relative to gene transfer achieved with Ad5lucRGD
alone. The neutralizing antibody (NAb) titer was determined as the lowest degree of dilution that
blocked gene transfer by more than 80 % (Pesonen et al., 2009).
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5. Ethical aspects and considerations
Human samples: Blood  samples  were  collected  to  monitor  the  safety  of  treatment  and  also  for
treatment efficacy analysis. This caused additional but acceptable harm for patients. Tumor samples
were collected and analyzed for cox2 status in study II but this caused no extra harm to patients
because  tumor  tissue  samples  were  already  available  due  to  prior  standard  surgical  resection.
Ascites samples were gathered during ascites removal in order to relieve patients’ symptoms. All
samples were processed anonymously and used only for intended purposes. Treatment protocols
were approved by the Surgical Ethics Committee of Helsinki University Central Hospital and
fulfilled the legal requirements.
Radiological analysis: To  monitor  radiological  responses  CT  or  PET-CT  scans  was  taken  when
suitable and this caused additional but acceptable ionizing radiation dose to patients. MRI imaging
caused no biological harm to patients.
6. Statistics (I-IV)
In  Study  I,  luciferase  and  GFP  expression  were  analyzed  with  a  two-tailed  t-test.  In  Study  II,
correlations between baseline neutralizing antibody titer and viral genomes in the serum and
between viral dose and transaminase increases were analyzed with Pearson correlation analysis.
Non-parametric Spearman's Rho analysis was used to evaluate correlations between archival tumor
Cox-2 expression and viral genomes in the serum, and between route of administration and adverse
events.  In  Study  IV,  a  two  tailed  t-test  was  used  to  assess  significance  in  T-cell  phenotype  data,
while non-parametric one-way ANOVA, with Dunn’s multiple comparisons post-test was used for
cytokine  data.  Responses  and  correlation  to  ELISPOT  data  were  analyzed  with  Chi2- and Mann-
Whitney-U tests. Anti-tumor and anti-viral T-cell induction was calculated with two-tailed Fisher’s
exact test. In Studies II, III and IV, patient survival data was processed with Kaplan-Meier analysis
and Log-Rank test (Study IV). All analyses were done with SPSS 15.0 software for Windows and a
p-value less than 0.05 was considered statistically significant.
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RESULTS AND DISCUSSION
1. Preclinical results (I)
1.1 The combination of radiotherapy and adenoviral gene therapy
Radiotherapy is important in the treatment of prostate cancer and breast cancer and it is widely
used in many other malignancies. Prostate and breast cancer are the most common cancers
worldwide. Because of this clinical relevance, we studied the combination of radiotherapy and
adenoviral gene therapy in vitro using a prostate cancer cell line (PC-3MM2) and a breast cancer
cell line (M4A4-LM3). In one experiment, lung cancer cell line LNM35/eGFP was also used.
Radiation can increase adenoviral transgene expression both in vitro and in vivo. However, the
exact molecular and cellular mechanisms underlying this effect have remained largely elusive
(Hingorani et al., 2008b; Vereecque et al., 2003; Zhang et al., 2003a). These mechanisms are
clinically relevant, because radiation can enhance the expression and effect of therapeutic
transgenes such as interleukins or GM-CSF. There is evidence that some modifications in viral
structure might hinder or change the effect in an unfavourable way. Hingorani et al reported that
radiation increased GFP expression only under the Egr-1 promoter, but not with the CMV promoter
(Hingorani et al., 2008a) and the effect was cell line dependent.
 These findings created a need to study these aspects more carefully. We have focused, in this
study, on investigating the synergistic mechanisms only in vitro, because most of the unresolved
questions remain at the cellular level.
1.2 Radiotherapy increases adenoviral transgene expression, regardless of the transgene,
promoter, cancer cell line, or radiation dose
M4A4-LM3 and PC-3MM2 cells were radiated with 8 Gy single dose and infected with five
different replication-deficient adenovirus vectors 24 h post irradiation. Adenoviruses were capsid
modified, allowing us to further study the role of capsid modification in transgene expression. In
this experiment luciferase was used as a transgene and its activity was measured 24 h post infection.
As a conclusion, radiation enhanced luciferase expression in both cell lines, with all tested viruses
and all concentrations compared to nonradiated controls (see Figure 1 and Supplementary Table 1
in study I).
To study whether the enhancement of transgene expression is promoter specific, radiated PC-
3MM2 cells were infected with viruses with identical capsids but different promoters (one virus
promoter: cytomegalovirus (cmv) and four human promoters: multi-drug resistance (mdr), ?-
lactalbumin (ala), cyclo-oxygenase 2 (Cox2), and vascular endothelial growth factor (VEGF)).
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Radiation enhanced luciferase expression with all tested promoters (see Figure 2, panel A and
Supplementary Table 1 in study I), except the vascular endothelial growth factor promoter. This
promoter was further studied in two additional cell lines (M4A4-LM3 and LNM35/eGFP)
Statistically significant enhancement was seen in M4A4-LM3 cells (see Figure 2, panel B in study
I). These results suggest that many different types of promoters are susceptible to induction by
radiation.
We also measured the expression of GFP to see if the effect of radiation depended on the reporter
transgene. PC-3MM2 cells were radiated with 8 Gy dose and infected with two different viruses
expressing GFP (Ad5-GL and Ad5-pk7-GL). Flow cytometric analyses showed that also GFP
expression was enhanced similarly as luciferase expression (see Figure 2, panel C in study I).
Overall, average radiation induced enhancement of transgene expression was 146 % (range: 0 % ?
274 %).
Finally, the impact of radiation dose on luciferase expression was tested in M4A4-LM3 cells.
Radiation increased luciferase expression with all tested doses (dose range: 0.5 Gy – 15 Gy) (see
Figure 2, panel D in study I). It is interesting to note that the 2 Gy dose, which is an important dose
from a clinical perspective, increased transgene expression significantly (+ 110 %) yet the higher
doses seemed to be slightly more effective (maximum effect + 136 % at 12 Gy).
Our results are in line with previous results published by Hingorani et al. They showed that NIS,
GFP, ?-galactosidase (lacZ) and luciferase expression was increased due to radiation. These results
were obtained in colorectal, head and neck and lung cancer irrespective of promoter (CMV, RSV,
hTR, hTERT) and were also confirmed in vivo (Hingorani et al., 2008b).
1.3 Radiation upregulates HSP90 and both RNA and protein production
The effect of radiation in all cell types is quite unspecific. Reactive oxygen species can damage
many cell organelles and disturb the global cell microenvironment as well as alter cell metabolism
(Hallahan, 1996). Based on this, we used mass spectrometry analysis to find possible differences
between irradiated and non-irradiated cancer cells that might contribute to the findings above.
M4A4-LM3  cells  were  radiated  with  an  8  Gy  dose  and  24  h  post  radiation,  mass  spectrometry
analysis was performed. The analysis revealed the up-regulation of HSP90 in irradiated cells (see
Supplementary Table 2 in study I). The up-regulation of heat shock proteins by cell stress, such as
radiation  is  well  known  and  it  prompted  us  to  study  further  the  role  of  HSP90  in  the  context  of
adenoviruses and radiation.
We also studied radiation induced alterations in cell metabolism and protein production. M4A4-
LM3 and PC-3MM2 cells were exposed to an 8 Gy dose which resulted in higher total protein
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levels in irradiated cells measured at 24 h after radiation (see Figure 4, panel B in study I). In the
M4A4-LM3 cell line, the total RNA levels were quantified also 24 h and 48 h after radiation. RNA
levels increased 149 % and 71 %, respectively (see Figure 4, panel A in study I). Flow cytometric
analysis was used to measure the effect of radiation on cellular GFP expression in M4A4-LM3 and
LNM35/eGFP cells. In both cell lines, radiation enhanced cellular GFP levels (see Figure 4, panels
C and D in study I).
In summary, it seems that radiation upregulates specific proteins like HSP90, but probably there
are also unspecific changes in cell metabolism and protein production that might contribute also to
the expression of foreign genes, such as genes from adenovirus vectors. Our unpublished results
indicate that when M4A4-LM3 cells were exposed to heat shock, there was no effect on adenovirus
transgene expression contrary to radiation (Figure 9). Zacal et al reported  similar  results  in  colon
carcinoma (Zacal et al., 2005). This data supports the hypothesis that radiation alters cell
microenvironment in such a way that it favors adenovirus gene expression and the effect cannot be
obtained by any random stress to cancer cells.
Figure 9. M4A4-LM3 cells were exposed to
heat  shock  (that  is  4  h  at  +  42  °C)  and  then
infected 4 h later with Ad5luc1 (200 VP/cell).
No increase was seen in luciferase levels
compared to nonradiated controls. However, in
the same experimental design, an 8 Gy dose
increased luciferase expression by 154 % (p <
0.001). Error bars = standard deviation.
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1.4 Radiation does not increase virus transduction or viral receptors
It has been suggested that radiation up-regulated gene expression could be explained by the
increased virus transduction to cancer cells due to increased adenovirus receptors. One of the
proposed effectors is upregulated Dynamin 2. Endocytosis of adenovirus to clathrin-coated vesicles
requires the action of the large GTPase dynamin as a constrictase (Takei et al., 1995). There are
reports in different cancer cell lines such as pancreatic and colon carcinoma that radiation
upregulates dynamin 2 expression, leading to increased adenovirus uptake and increased adenovirus
transgene expression (Egami et al., 2008; Qian et al., 2005). Qian et al also proposed that CAR does
not contribute to increased transduction. Conflicting findings were reported in colorectal, head and
neck and lung cancer where CAR and integrin-? levels increased after radiation (Hingorani et al.,
2008b).  However,  radiation  also  exerts  other  nontransductional  effects.  There  is  evidence  that
adenovirus receptor expression might be cell cycle dependent, possibly explaining these conflicting
results.  Both  CAR and ?v-integrin receptor showed increased cell surface availability in M-phase
(1.5-fold and 2- to 3-fold increases, respectively) (Seidman et al., 2001). This result also raises a
new opportunity to enhance adenovirus transgene expression by synchronizing cells to M-phase
with the clinically available chemotherapeutic paclitaxel.
In our study the levels of CAR, CD46, heparan sulfate proteoglycans, integrin ?3 and integrin ?5
were measured by flow cytometry. We could not detect any changes in the cell surface receptor
levels challenging some of the previous results (see Supplementary Figure 1 in study I). Viral DNA
content of cancer cells at 24 h after radiation has been reported to be significantly higher than that
of nonradiated (Egami et al., 2008). Contrary to that, our findings showed unchanged viral DNA
content at 2 h and 24 h after infection regardless of radiation status (see Figure 3 in study I). In
brief, our data support the hypothesis that radiation does not affect adenoviral transduction or
receptor availability, but the mechanism is related to post-transductional events.
1.5 Enhancement of transgene expression is mediated through genotoxic stress regulation
and repair
The radiation-induced enhancement of adenovirus transgene expression was previously explained
by alterations in receptors relevant for adenovirus transduction. However, during recent years the
focus in this research area has been in radiation induced DNA damage and further cellular signal
transduction that favours adenovirus transgene expression. Many of these signal transduction
pathways belong to the mitogen activated protein kinase (MAPK) superfamily and multiple MAPK
pathways are activated following radiation and other toxic stress (Dent et al., 2003).
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Increased adenovirus transgene expression has been reported after exposure of cells to various
DNA damaging agents, such as cisplatin and N-acetoxy-acetylaminofluoride (Park et al., 2002;
Zacal et al., 2005). The inhibition of radiation induced DNA damage repair by targeting DNA-
dependent protein kinases (DNA-pk) is also associated with increased transgene expression from
adenoviral vectors (Hingorani et al., 2008a).
The compact and supercoiled DNA double helix requires topological modifications during cellular
processes such as transcription, replication, and repair (Gilbert et al., 2012). These modifications are
executed by topoisomerase enzymes, and topoisomerase inhibitors such as topotecan and irinotecan
have been widely used in the treatment of colorectal  cancer (Gilbert  et  al.,  2012).  Topoisomerase
inhibitors can also potentiate the effect of radiotherapy by inhibiting DNA damage repair (El-
Khamisy et al., 2007). Zamir et al reported that adenoviruses induced host topoisomerase activity
and inhibition of topoisomerase-I by topotecan enhanced adenovirus transgene expression in
hepatic cells, colon cancer cells and prostate cancer cells (Zamir et al., 2007).
HSP90 is an ATP-dependent molecular chaperone that regulates the late-stage maturation,
activation and stability of a diverse range of client proteins including protein kinases (Pearl et al.,
2008). Although HSP90 is highly expressed in normal cells, where it helps to maintain protein
homeostasis, HSP90 is also recruited by cancer cells to help mutated oncoproteins and buffer
cellular stresses induced by oncogenesis (Neckers and Workman, 2012). HSP90 overexpression is
related to poor prognosis (Pick et al., 2007) and it plays a versatile role by regulating a large number
of cellular kinases and transcription factors (Ciocca and Calderwood, 2005). HSP90 inhibitors (e.g.
tanespimycin, 17-AAG) are clinically very interesting because they sensitize tumor cells to
radiation (Machida et al., 2003) and many of them are being tested in clinical trials with promising
results (Modi et al., 2011; Neckers and Workman, 2012).
All these data support the hypothesis that radiation-induced transgene expression is mediated by
persistent DNA damage and genotoxic stress regulation. Several factors (e.g. DNA dependent
protein kinase inhibitors (DNA-PKi), topoisomerase-I inhibitors (Topo-i) or HSP90 inhibitors
(HSP90i)) associated with DNA damage might also contribute to adenoviral transgene expression
enhancement with radiation and thus we wanted to clarify this issue further.
DNA damage repair inhibitors combined with radiation were studied to evaluate the effect of
genotoxic stress modulation on adenoviral transgene expression in M4A4-LM cells.
Immunofluorescence analysis for phosphorylated histone H2AX (?H2AX)  foci  was  used  as  a
marker of double strand break (DSB) repair.
HSP90i increased radiation-induced DNA damage (see Figure 5, panel G in study I), but there was
no correlation between DNA damage and transgene expression. Actually HSP90i decreased
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adenovirus transgene expression regardless of radiation status (see Figure 6 in study I). It is possible
that cellular and perhaps mutated heat shock proteins in M4A4-LM3 cells try to maintain
oncogenesis (e.g. interfere with p53), but most likely HSP90i is anyhow able to counteract this at
least partly, leading to down-regulation of adenoviral proteins. From a clinical point of view, it
seems that the combination of adenoviruses and heat shock protein inhibitors is not favourable in
the context of therapeutic transgenes.
 Topo-i increased adenovirus transgene expression with and without radiation by +295 % and 134
%, respectively (see Figure 6 in study I). Topo-i increased also the number of DSBs with virus, but
there was no additional effect with radiation (see Figure 5, panel F in study I).
DNA-PKi alone had only a modest effect to transgene expression (+11 %), but it greatly enhanced
transgene expression with radiation (+499 %) (see Figure 6 in study I). Also, a previously
unreported correlation between the number of DSBs and adenovirus transgene expression was
detected (see Figure 5, panels F and G in study I). This result suggests that there is a relation
between DNA damage and adenovirus transgene expression and this relation can be modified with
inhibitors involved in DNA damage repair. The most probable signal transduction pathway that
links these findings is the MAPK pathway. However, p38/mitogen activated protein kinase
inhibition did not enhance adenovirus transgene expression (Hingorani et al., 2008a). Thus, more
studies are needed to specify the roles of different MAPK pathways in vivo.
All these data together indicate that radiation has various different effects that contribute in
concert to the enhanced transgene expression from adenovirus vectors. Perturbations in cell
metabolism and protein production induce additional alterations in intracellular signaling
environment that favours adenovirus gene expression. Specifically, MAPK/ERK and PI3K pathway
signaling  have  been  implicated.  Radiation  also  induces  a  transcriptional  effect  via  the  NF-?B
pathway by altering transcription of genes involved in cell cycle arrest and DNA repair (Vereecque
et al., 2003). In addition, radiation has been shown to increase genetic recombination facilitating
adenoviral transgene expression (Gridley and Slater, 2004; Stevens et al., 2001). Radiation induced
genetic hyper-recombination which was rather long-lasting up to three days, and thus facilitated
viral gene expression (Stevens et al., 2001). Adenoviral genes from the E4 region also have
properties that favor adenovirus transgene expression even without radiation and it is possible that
also this feature is enhanced by radiation (Weitzman and Ornelles, 2005). However these E4 region
dependent functions require at least in part the E1B55k protein, which is not present in E1 deleted
viruses that were used in this study.
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1.6 Translational relevance and limitations
Radiation has a positive effect on adenovirus transgene expression both in vitro and in vivo in
various tumor cell types. The combination of radiation and adenovirus gene therapy suggests
additional or even synergistic effects. In study I, the combination of radiotherapy and adenovirus
gene therapy revealed a possible synergy mechanism with chemotherapeutics as well. This was also
first time according to our knowledge, when a HSP90 inhibitor, DNA-PK inhibitor, and
topoisomerase inhibitor were studied together with radiation and adenoviruses. Based on these
results, it would be rational to combine adenoviruses with radiotherapy in the treatment of prostate
or breast cancer. Radiotherapy could enhance therapeutic transgene expression from intratumorally
injected adenovirus vectors. Because in this setting both treatments are local, the adverse events
reactions could be better tolerated, but local anti-tumor effects could be enhanced. Intratumoral
injection to prostate and breast tissue is rather easy and practically possible. The combination could
be further improved by agents preventing DNA damage repair, such as DNA-pk inhibitors.
There are also some limitations in this study. Radiotherapy is usually given in small daily doses
(fractions)  and  thus  the  whole  treatment  protocol  takes  several  weeks.  In  this  study  we  have  not
studied the effect of fractionated radiotherapy and this significantly limits the translation of these
results to clinical reality. For example, a typical breast cancer radiotherapy protocol takes five
weeks (total dose 50 Gy, given in 2 Gy fractions per day) and it is not known how adenoviruses
should be administered in this context and how fractionated radiation affects adenovirus transgene
expression. There are technical and practical problems that prevent us from performing an in vivo
experiment. For example, mice cannot be irradiated daily, the immobilization of mice during
irradiation is not possible, which limits the dose delivery to tumors.  Finally, we have studied
transgene expression only from replication-deficient adenovirus vectors, but oncolytic/conditionally
replicative adenoviruses would be even more relevant. Probably there are no major differences
between replication-deficient and oncolytic adenoviruses regarding transgene expression. In theory,
transgene expression from oncolytic adenoviruses (e.g. E1A deleted) should be more effective due
to viral replication and an intact E1B55k/E4orf6 complex that potentiates the DNA damage induced
by radiation.
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2. Clinical results (II, III, IV)
2.1 Adenovirus therapy shows good safety in cancer patients
In study II the safety of Ad5/3-cox2L-d24 was studied in 18 patients (see Table 2 in study II). In
study III the safety of ICOVIR-7 was studied in 21 patients (see Table 2 in study III) and finally in
more versatile design, the safety of various oncolytic viruses was studied in 124 patients in Study
IV (see Table 2 and Supplementary Table 1 in study IV). All treatments were performed as part of
the Advanced Therapy Access Program (ATAP) as described in Material and Methods (see section
4.1).  Note,  that  ATAP is  not  a  clinical  trial.  In   studies  II  and  III,  one  oncolytic  virus  as  a  single
therapeutic agent was used for each patient cohort and in study IV, several oncolytic viruses were
used as a single therapy or serial therapy. Altogether 157 patients with advanced metastatic tumors
were treated and in total six different oncolytic virus constructs were used.
The most common detected adverse events are summarized in Table 12. Adverse events are
categorized as hematological adverse events, known also as non-clinical adverse events because
most of them are laboratory findings without any clinical symptoms or known clinical relevance.
Clinical adverse events are findings that cause clinical symptoms for patients and may need medical
intervention.
The most common detected grade 1 or 2 hematological adverse events were (Table 12): anemia
(36.1 – 81.0 %), leukocytopenia (22.2 – 100.0 %), and elevated liver enzymes (39.2 – 77.8 %). The
most common detected grade 1 or 2 clinical adverse events were (Table 12): injection or tumor site
pain (4.8 - 28.6 %), any other pain (83.3 – 100.0 %), nausea or vomiting (38.1 – 90.5 %), fever
(50.0 – 90.5 %), and fatigue (55.6 – 78.4 %). No grade 4 adverse events were seen in studies II and
III, but in study IV, six patients had grade 4 adverse events (Table 12). The most likely explanation
for this is a higher number of enrolled patients.
Hazard analysis was done for each adverse event. The term serious adverse event (SAE) was
applied  if  the  adverse  event  was  possibly  or  probably  treatment  related  and  it  resulted  in  patient
hospitalization, prolongation of hospitalization, life threatening situation or death. Altogether there
were thirteen serious adverse events in eleven different patients (Single treatment: six patients,
Serial treatment: four patients, both treatments: one patient in study IV (see Supplementary Table 3
in study IV and Table 12). No treatment related deaths occurred in any studies. In brief, adenovirus
gene therapy with different virus modifications or multiple dosing was safe.
It has been proposed that cytokines might be able to predict harmful inflammation and elevated
levels are known to be associated with systemic inflammatory response syndrome (SIRS) and may
induce a multi organ failure (MOF) (Brunetti-Pierri et al., 2004; Raper et al., 2003). In our study,
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blood inflammatory cytokine level analysis was performed for each patient. IL-6, IL-8 and TNF-?
were selected for safety analysis due their pro-inflammatory role (Mistchenko et al., 1994;
Stenvinkel et al., 2005) and IL-10 because of its anti-inflammatory nature. The analysis did not
reveal high cytokine levels in any of the studies emphasizing the favourable safety profile of these
adenovirus treatments.
All adenovirus cancer gene therapy trials carried out throughout the world so far have shown good
safety and thousands of patients have been enrolled. No treatment related deaths have been
reported. For comparison, just in one monoclonal antibody trial (Ibilimumab), 14 treatment related
deaths occurred (2.1 % of patients) (Hodi et al., 2010). The most common adverse events in
adenovirus trials have been flu-like symptoms (fever, fatigue, chills/rigors, nausea/vomiting) and
also mild to moderate pains are usually seen. The safety profile in our studies is consistent with
these reports.
The  primary  aim  in  study  IV  was  to  evaluate  the  safety  of  serial  treatment  (=  three  rounds  of
adenovirus treatment within 10 weeks) compared to a single therapy. In single therapy groups grade
4 adverse events were seen in 2.6 ? 2.8 % of patients and in 3.9 – 4.8 % of patients with serial
treatment, and serious adverse events 5.6 – 7.7 % vs. 4.8 ? 7.8 %, respectively. These data suggest
that  serial  treatment  is  as  safe  as  a  single  round  of  therapy.  However,  the  overall  probability  for
grade 3 and grade 4 adverse events was slightly higher in certain serially treated cohort (grade 3: 23
% vs. 33 % and grade 4: 3 % vs. 5 %, see Supplementary Table 2 in study IV). This is explained by
the accumulation of adverse events during repeated dosing.
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Table 12. Summary of the  most common detected adverse events according to CTCAE v3.0 criteria
# Serious adverse event analysis include all grades (1 – 4)
* One patient reported in both groups
Study II Study III Study IV
Adverse events Single
(N = 18)
Single
(N = 21)
Single
(N = 39)
Serial
(N = 21)
All CGTG-102
(N = 115)
Single
(N = 72)
Serial
(N = 51)
Hematological (gr. 1 - 2):
anemia 50.0 % 57.1 % 61.5 % 81.0 % 42.6 % 36.1 % 45.1 %
leukocytopenia 22.2 % NA 87.1 % 100.0 % 48.7 % 47.2 % 43.1 %
elevated liver enzymes 77.8 % 61.9 % 51.3 % 71.4 % 42.6 % 40.3 % 39.2 %
Clinical (gr. 1 - 2):
injection site pain/tumor 16.7 % 4.8 % 12.8 % 28.6 % 26.1 % 22.2 % 27.5 %
other type of pain 83.3 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 %
nausea, vomiting 61.1 % 38.1 % 46.2 % 90.5 % 57.4 % 38.9 % 74.5 %
fever 50.0 % 85.7 % 89.7 % 90.5 % 81.7 % 72.2 % 82.0 %
fatigue 55.6 % 76.2 % 71.8 % 76.2 % 72.2 % 59.7 % 78.4 %
Hematological (gr. 3):
anemia 0.0 % 4.8 % 0.0 % 4.8 % 3.5 % 4.2 % 2.0 %
leukopenia 0.0 % 0.0 % 23.1 % 52.4 % 16.5 % 23.6 % 3.9 %
elevated liver enzymes 0.0 % 0.0 % 7.7 % 9.5 % 5.2 % 5.6 % 3.9 %
Clinical (gr. 3):
injection site pain 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %
other type of pain 0.0 % 0.0 % 2.6 % 0.0 % 7.0 % 8.3 % 3.9 %
nausea, vomiting 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0%
fever 0.0 % 0.0 % 0.0 % 4.8 % 2.6 % 1.4 % 3.9 %
fatigue 0.0 % 0.0 % 0.0 % 0.0 % 3.5 % 2.8 % 3.9 %
All grade 4 (no. of patients) 0 0 1 (2.6 %) 1 (4.8 %) 4 (3.4 %) 2 (2.8 %) 2 (3.9 %)
Serious adverse events #
(no. of patients)
0 0 3 (7.7 %) 1 (4.8 %) 7 (6.1 %) 4* (5.6 %) 4* (7.8 %)
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2.2 Neutralizing antibodies and virus in circulation
Neutralizing antibody titer measurements were used to evaluate immunological responses in the
patients following the adenovirus treatment. In addition, viruses in the circulation were measured by
quantitative real time polymerase chain reaction (qPCR).
Neutralizing antibody measurements were done for all patients in studies II and III, except one
patient  in  study  II  (sample  was  not  available)  (Table  13).  More  than  half  of  the  patients  in  both
studies (82.4 % and 57.1 %, respectively) had positive antibody titers before treatment, indicating
natural pre-existing immunity (Table 13). In study II, Ad5/3-cox2L-d24 induced increased antibody
titers for all patients, whereas ICOVIR-7 induced increasing titers for 76.2 % of patients. These
lower numbers of increased titers seemed to correlate with lower pre-existing antibodies for
ICOVIR-7. It remained unclear why the number of positive pre-treatment patients was lower for
ICOVIR-7, since there were no major differences in patients’ pre-treatment profiles.
All patients in studies II, III and IV were negative for viral genome in circulation before treatment,
as expected. After the treatment, most of the patients (range: 83.3 - 94.7 %) were positive for virus
in blood (Table 13). The highest detected virus concentration was seen in a patient with prostate
cancer (see Table 4 in study II). This patient belonged to the highest dose cohort of Ad5/3-cox2L-
d24 (3 x 1011 VP) and was highly positive for cox2L expression based on the pre-treatment analysis
of the tumor block, suggesting effective viral replication. The viral replication in patients is anyhow
a debatable issue because the highest detected total viral load (if blood volume 5000 ml ? total
virus load was 2.63 x 1010 VP) was 10-fold less than the total injected dose (3 x 1011 VP). However,
high viral concentration did not impact patient’s survival (44 days) regardless of stable disease
response based on tumor marker analysis (see Table 4 in study II). Interesting results were seen in
study IV, where internal survival comparison was possible based on study design (see next section
2.4). There were more viral genome positive patients in the single treated group (94.7 %) compared
to the serially treated patients (85.0 %) (Table 13), but survival was better for serially treated (Table
14). The high viral concentrations were detected both in serial and single treatment patients. There
were no differences in the mean or median titers (see Table 1A in study IV).
In conclusion, the highest viral concentrations were seen usually 2-4 days after treatment and were
detectable in some patients for several weeks. The frequency of post-treatment virus positive serum
samples seemed to increase with the injected viral dose.
In an earlier phase I/II prostate cancer trial, all patients developed antibodies to oncolytic
adenovirus CG7870, but no complete or partial responses were seen based on PSA levels (Small et
al., 2006). Five out of twenty-three patients had decreased PSA levels, resulting in 21.7 % disease
control. Small et al also reported interesting “secondary” or “delayed” peaks for virus presence in
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plasma typically between day 2 and day 8, suggesting virus replication in 70 % of the patients.
Nevertheless, our data and most other trials support the conclusion that usually the best treatment
responses are seen with high injected viralk doses and high injected doses correlate with high
detected doses.
Table 13. Summary of adenovirus antibody titers and qPCR data detecting adenovirus genome in
circulation in studies II, III and IV.
Neutralizing antibodies qPCR
Study II (N = 18) Number of evaluable patients: Number of evaluable patients:
17 18
Single (N = 18) Pre-treatment baseline: Pre-treatment baseline:
14 positive (82.4 %) all negative
Increasing titers: Post-treatment:
17 patients (100.0 %) 15 positive (83.3 %)
Highest titer: Highest concentration:
16384 5 259 766 VP/ml
Study III (N = 21) Number of evaluable patients: Number of evaluable patients:
21 21
Single (N = 21) Pre-treatment baseline: Pre-treatment baseline:
12 positive (57.1 %) all negative
Increasing titers: Post-treatment:
16 patients (76.2 %) 18 positive (85.7 %)
Highest titer: Highest concentration:
16384 4 038 049 VP/ml
Study IV (N = 124) Number of evaluable patients: Number of evaluable patients:
0 single 38, serial 20
Single (N = 39) NA Pre-treatment baseline:
all negative
Post-treatment:
36 positive (94.7 %)
Highest concentration:
72 613 VP/ml
Serial (N = 21) NA Pre-treatment baseline:
all negative
Post-treatment:
17 positive (85.0 %)
Highest concentration:
611 235 VP/ml
CGTG-102 (N = 115)
Single (N = 72) NA NA
Serial (N = 51) NA NA
NA = data not available, VP = virus particle
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2.3 Evidence of immunological T-cell activity
In study IV, we also evaluated T-cell responses against tumor and adenovirus by ELISPOT for
both  single  and  serially  treated  patients.  In  the  first  part,  31  %  of  single  treated  patients  had
increased tumor-specific CD8+ T-cells, whereas increased CD8+ T-cells were observed in 43 % of
serially treated patients, showing more T-cell induction for serially treated patients. The
corresponding numbers for decreased T-cells in blood were 28 % and 43 %, respectively. Decreased
CD8+ T-cells might indicate T-cell trafficking to tumor and positive response to adenovirus
treatment.  So,  less  anergy  (no  induction  or  trafficking)  was  seen  for  serially  treated  patients  (see
Figure 1 in study IV). Seventy two percent (28/39) of single treated and 90 % (19/21) of serially
treated patients demonstrated increasing levels of Ad5-specific CD8+ T-cells (see Supplementary
Figure 3 in study IV). These data raise the possibility that immunological factors might contribute
to treatment response and survival.
2.4 Evidence of anti-cancer efficacy
RECIST analysis (Therasse et al., 2005; Therasse et al., 2006) based on radiological response or
measurements of tumor markers in the blood have been used to quantify the effect of a tested
treatment in oncology. However, these methods are not optimal for various reasons and they are
even less optimal for most modern therapies.  A notable example was seen in a phase III clinical
trial of sipuleucel-T (Provenge), a cell based immunotherapy for advanced prostate cancer, where
only one out of the 341 patients in the active arm showed a partial response according to RECIST,
and only 2.6 % of patients had ? 50 % reduction in PSA levels. Still, a 4.1 month improvement in
the median survival (25.8 months vs. 21.7 months) was achieved and the drug was approved by
FDA in April, 2010 (Kantoff et al., 2010; Mellman et al., 2011). Progression free and overall
survival is considered the most accurate method to monitor treatment efficacy. In addition to these
efficacy indicators, attention in oncology trials are given also to other aspects of treatment
suitability like quality of life, adverse event profile and the costs of treatment.
Efficacy analysis of oncolytic viruses is very challenging. First, local viral replication in tumors
might cause inflammation that enlarges the tumor, leading to incorrect radiological interpretation of
disease status. This phenomenon is sometimes called pseudoprogression. Both PET-CT and MRI
imaging are sensitive for inflammation too, so they are unlikely to solve this problem. Secondly,
lytic processes in tumor cells due to virus replication might release tumor markers to the circulation
and cause false positive marker responses. Thirdly, there are no generally accepted and reliable
methods to measure other clinically relevant responses, such as reduction of ascites or reduction of
pleural fluid. Histological response evaluation is a method where tumor regression grading after
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therapeutic intervention is evaluated by tissue samples (Rubbia-Brandt et al., 2007). This would be
suitable and objective for adenovirus treatment as well, but histological response evaluation is
possible only for neo-adjuvant treatment before surgical resection and this is not common in
adenoviral cancer gene therapy.
Guidelines  for  the  evaluation  of  immune therapy  activity  in  solid  tumors  have  been  created  and
could be applied to adenovirus treatments (Wolchok et al., 2009). Four immunological response
patterns have been detected and these results have been translated into new response criteria called
the immune-related response criteria (irRC). The four response patterns in irRC classification are:
(i) shrinkage in baseline lesions, without new lesions; (ii) durable stable disease (in some patients
followed by a slow, steady decline in total tumor burden); (iii) response after an increase in total
tumor burden; and (iv) a response in the presence of new lesions. All patterns were associated with
favorable survival (Farolfi et al., 2012; Wolchok et al., 2009).
The  disease  control  (=stable  disease  or  better)  according  to  RECIST was  40.0  % with  oncolytic
adenovirus Ad5/3-cox2L-d24 in study II, and 41.7 % with ICOVIR-7 in study III (Table 14).
Disease controls in these studies based on tumor markers were 70.6 % and 23.1 % and median
survivals 107 days and 92 days, respectively. Due to the study design, there are no control groups in
either of the study and the efficacy cannot be directly estimated. However, these results are
promising, since all patients had a progressive tumor before viral treatment.
In study II, one patient with neuroblastoma showed partial response (71.1 % reduction in the
tumor volume and 33.0 % reduction in the longest diameter) one month after treatment and his bone
marrow was also free of disease for first time since diagnosis (see Figure 3 in study II). Bone
marrow biopsies showed disease relapse 3 months later. In study III, a 9-year-old boy with Wilms
tumor had partial response with a 37 % overall reduction in the sum of tumor diameters (see Figure
1 in study III). In addition, two patients in study II had long-lasting stable disease response, 93 days
and 316 days, respectively. Besides, the tumor density of one patient decreased by 16 %, which
might also indicate benefit (Park et al., 2008) based on Choi criteria.
In study IV, 124 patients were enrolled. In the first part of the study, 60 patients were treated once
(=  single  therapy,  39  patients)  or  three  rounds  (=  serial  therapy,  21  patients).  Altogether  six
different oncolytic viruses (Ad5/3-d24-GMCSF a.k.a CGTG-102, Ad5-d24-GMCSF, Ad5-RGD-
d24-GMCSF, Ad5/3-cox2L-d24, ICOVIR-7 and Ad3-hTERT-EI) were used, making this patient
population and the treatment protocol more heterogeneous than  in the later part of the study, where
we focused more on Ad5/3-d24-GMCSF (=CGTG-102 virus). In the latter part, altogether 115
patients were enrolled (including 51 patients from first part). Two major differences exist in study
IV  compared  to  studies  II  and  III.  First,  serial  treatments  were  not  used  in  studies  II  and  III.
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Secondly, single treated patients were used as a control group for serial treated patients in study IV,
but because the study design is not a randomized trial, all results should be interpreted carefully.
The radiological disease controls (=stable disease or better) in study IV for single treated patients
were 40.9 % and 74.0 %, and for serial treated 50.0 % and 48.0 % (Table 14). Disease control
measured by tumor markers were 38.1 % and 58.0 % for single treated, and 37.5 % and 48.0 % for
serial treated (Table 14). Based on disease control results, single treatments were more effective and
favorable. However, the survival data suggested benefit for serial treated patients yet the difference
was not statistically significant (Table 14). In the first part, the survival difference was 141 days and
in the latter part 166 days. Survival at 200 days was also better for serial treated patients. Twenty-
two patients received three different viruses in a serial treatment in a first-in-humans application of
sero-switching with oncolytic viruses (see Table 2 in study IV). The reason for sero-switching is the
opportunity to avoid pre-existing neutralizing antibodies. Median survival for these patients was
241 days and therefore the theoretical advantage of avoiding neutralizing antibodies (Hemminki et
al., 2002; Kanerva et al., 2002b; Raki et al., 2011; Sarkioja et al., 2008) did not manifest in the
survival advantage. For patients with CGTG-102 only, the median survival was 291 days.
These results indicate that serial treatment might be more effective. As stated earlier, the survival
and efficacy data showed here is only preliminary and should be interpreted with caution, because
these studies are not randomized trials and other factors might also contribute to the results.
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Table 14. Summary of anti-tumor efficacy observed in patient series.
Study Design RECIST Tumor Markers Median
Survival
Study II (N = 18) Number of evaluable patients:
5
Number of evaluable patients:
14
Number of markers: 17
Single (N = 18) PR: 1 (20.0 %) PR: 2 (12.0 %) 107 days
MR: 1 (20.0 %) MR: 4 (23.5 %)
SD: 0 (0.0 %) SD: 6 (35.0 %)
PD: 3 (60.0 %) PD: 5 (29.5 %)
Study III (N = 21) Number of evaluable patients:
12
Number of evaluable patients:
10
Number of markers: 13
Single (N = 21) PR: 1 (8.3 %) PR: 0 (0.0 %) 92 days
MR: 2 (16.7 %) MR: 2 (15.4 %)
SD: 2 (16.7 %) SD: 1 (7.7 %)
PD: 7 (58.3 %) PD: 10 (76.9 %)
Study IV (N = 124) Number of evaluable patients: Number of evaluable patients:
single 22, serial 18 single 21, serial 8
Single (N = 39) PR: 0 (0.0 %) PR: 1 (4.8 %) 128 days
MR: 1 (4.5 %) MR: 2 (9.5 %) 35 %*
SD: 8 (36.3 %) SD: 5 (23.8 %)
PD: 13 (59.1 %) PD: 13 (61.9 %)
Serial (N = 21) CR: 1 (5.6 %) CR: 0 (0.0 %) 269 days
PR: 1 (5.6 %) PR: 2 (25.0 %) 57 %*
MR: 2 (11.1 %) MR: 1 (12.5 %)
SD: 5 (27.8 %) SD: 0 (0.0 %)
PD: 9 (50.0 %) PD: 5 (62.5 %)
CGTG-102 (N = 115) single 23, serial 22 single 26, serial 29
Single (N = 72) Disease control 74 % Disease control 58 % 111 days
37 %*
Serial (N = 51) Disease control 48 % Disease control 48 % 277 days
58 %*
Summary of
disease controls#:
Study II 40.0 % 70.6 %
Study III 41.7 % 23.1 %
Study IV
Single (N = 39) 40.9 % 38.1 %
Serial (N = 21) 50.0 % 37.5 %
Single (N = 72) 74 % 58 %
Serial (N = 51) 48 % 48 %
CR: Complete response, PR: Partial response (>30 % decrease), MR: Minor response (10 – 30 %
decrease), SD: Stable disease (< 20 % increase), PD: Progressive disease (? 20 % increase or new
lesions), # Disease control = stable disease or better, * survival at 200 days
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2.5 The relevance of clinical studies and limitations of adenovirus therapy
According  to  our  knowledge,  ICOVIR-7  in  study  III  was  the  first  RGD-modified  oncolytic
adenovirus used to treat cancer patients. The first tropism-modified oncolytic adenovirus studied in
a clinical phase I trial was Ad5-d24-RGD (Kimball et al., 2010). Twenty-one patients with recurrent
gynecologic disease were treated daily for three days in this trial. Clinical adverse events were
limited to grade 1 and 2 fever, fatigue and abdominal pain, no treatment related grade 3 or 4 adverse
events were seen and the maximum tolerated dose was not reached. No complete or partial
responses were seen, but 15 out of 21 patients had stable disease (= disease control 71.4 %).  Based
on tumor markers, disease control was observed in 7 patients (= disease control 33.3 %).
The safety profile of Ad5-d24-RGD was consistent with ICOVIR-7 in our study. The disease
control reported by Kimball et al was higher than what we saw in study III  (RECIST: 41.7 % vs.
71.4 % and tumor markers: 23.1 % vs. 33.3 %). The follow-up time in the phase I trial was only one
month, probably explaining this difference, because in our study the control images were acquired
about two months after treatment. Our study also included various different malignancies, whereas
only gynecological cancers were included in phase I trial by Kimbal et al and this might also have
an effect on the results.
Comparative analysis of different treatment protocols is still scarce. For example Small et al
(Small et al., 2006) used a single intravenous infusion, Kimball et al (Kimball et al., 2010) used
daily treatments for three days and Pan et al (Pan et al., 2009) used intratumoral injection once a
week for eight weeks. Treatment protocols should be based on pre-clinical results, but translational
problems, limitations in animal models and many practical issues play a role when treatment
protocols are selected. Our results showed that serial treatment is as safe as single treatment and
suggest that the treatment efficacy could be improved by multiple dosing.
The most extensive survival was seen in the serially treated cohort with CGTG-102 virus only
(291 days). This virus encodes GM-CSF as a transgene, suggesting that immunological responses
might be involved, at least partly, for the improved survival. In brief, based on clinical trial reports
and our data, it seems that viral modifications are not that crucial in determining the safety or
efficacy,  but  more  attention  should  be  aimed  at  interactions  of  the  viruses  and  the  host  immune
system.
Obviously  the  main  limitation  in  all  our  clinical  patient  series  is  the  fact  that  they  are  not
randomized clinical trials (which would have more rigorous patient selection and predefined
treatment protocol). Thus, these results should be verified eventually in randomized clinical trials.
Actually, a clinical trial with CGTG-102, sponsored by Oncos Therapeutics Ltd (Helsinki, Finland)
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is open and the first patients have been treated during summer 2012 (www.ClinicalTrials.gov,
NCT01437280). This is the first oncolytic virus trial ever performed in North Europe.
Instead of focusing on one cancer type, we have treated various solid advanced tumors. Some
might consider this heterogeneity as a confusing factor, but from a different perspective it can be
considered as a strength. It is very promising that the treatments showed benefits for many patients
regardless of their disease. It is also important to keep in mind that oncolytic adenoviruses have
been designed and developed to work in various cancer types.
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CONCLUSIONS AND FUTURE PROSPECTS
The modern viral cancer gene therapy era started roughly 25 years ago, but only two therapeutic
agents have been approved for clinical use in China, even though many sophisticated viruses have
been tested in various clinical trials with excellent safety and promising efficacy. There are
probably many reasons for this rather slow progress and more efforts are needed to study the
clinical validity of oncolytic virotherapy in treatment of cancer patients also in Europe and in U.S..
Insufficient funding and increasing complexity of pharmaceutical development limits the progress.
It has been estimated that the development of one new pharmaceutical agent will take roughly 20
years and cost at least 500 million euro. Such a huge amount of money and resources do not exist in
any university and thus the collaboration between commercial pharmaceutical companies and
academic research groups should be improved and encouraged. Increasing regulations and juridical
issues also complicate development, so some kind of reasonable balance should be found between
limiting control and uncontrolled freedom. Also, the novelty of gene therapy has been sometimes
more  of  a  burden  than  a  blessing  and  too  high  expectations  are  very  difficult  to  meet  (Sheridan,
2011).
It is still unknown how adenovirus gene therapy works eventually as a single therapy for less
advanced cancer patients, but the efficacy has been unsatisfying so far. Nevertheless, adenovirus
gene therapy seems promising and effective as a combination therapy underlined by the synergy
with radiotherapy, chemotherapeutics and other anti-cancer modalities. This is supported also by
our finding where radiation had a positive effect for adenovirus transgene expression in vitro in
various tumor types. The combination of radiotherapy and adenovirus gene therapy revealed a
possible synergistic mechanism with chemotherapeutics, giving a pre-clinical background for this
approach. Based on our results it would be rational to combine adenoviruses with radiotherapy and
the expression of therapeutic transgenes from adenoviral vectors could be enhanced in this setting
leading to better tumor control.
The safety of treatments in our clinical patient series was favorable. Altogether there were thirteen
(13) serious adverse events in eleven (11) different patients. So, severe adverse event probability
per patients was 7.0 %, which can be considered rather low compared to conventional therapies. We
studied six different oncolytic viruses in patients with advanced solid tumors, but there were no
major differences between the viruses regarding their safety or efficacy. However, CGTG-102
(Ad5/3-d24-GMCSF), which encodes immunostimulatory GM-CSF was perhaps the most
promising virus construct of the all six tested viruses. This evokes the possibility that viral
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modifications are not crucial, but immunological responses in patients eventually determines the
outcome.
More careful patient selection for adenovirus treatment based on analysis of tumor receptors (e.g.
CAR or desmoglein 2) or other tumor properties (e.g. Cox2 expression) might also improve the
treatment results in clinical trials. Treatment selection based on tumor properties is a common
clinical practice in oncology for many anti-tumoral agents. For instance, mono-clonal antibodies
such as Trastuzumab, are used for HER2 positive breast cancer only. However, it is known that
tumor properties might change during the years and for example 25 % of metastases with HER2-
positive breast cancer patients turn negative after treatment (Amir et al., 2012). Similar shifting
might take place in receptors relevant for adenovirus, hampering transductional targeting or other
specific modifications in vectors. Thus, pre-treatment properties must be interpreted with caution
and repeated tumor property determination is sometimes needed.
Viral cancer gene therapy is a very challenging field, because expertise from many areas such as
oncology, virology, and immunology is needed (Figure 10).  Faster progress in the field of viral
cancer gene therapy might take place if the fragmented knowledge could be combined more
efficiently. Especially, the importance of immunology has become evident during recent years and
probably immunological aspects will determine eventually the fate of the viral cancer gene therapy
field. The question is: “which happens first, fast virus eradication because of immune response
towards the virus, or the tumor eradication due to virus-induced immune response against tumor?”
If the latter happens, success might follow.
Figure 10. The dimensions of viral cancer gene therapy.
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